


# WEST Search History

DATE: Thursday, August 26, 2004

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L15	L14 AND calcium	1471
<input type="checkbox"/>	L14	GPCR	2183
<input type="checkbox"/>	L13	L12 AND calcium	459
<input type="checkbox"/>	L12	L11 AND GPCR	483
<input type="checkbox"/>	L11	536/23.5.CCLS.	8564
<input type="checkbox"/>	L10	L9 AND calcium	577
<input type="checkbox"/>	L9	L8 AND GPCR	615
<input type="checkbox"/>	L8	530/350.CCLS.	15141
<input type="checkbox"/>	L7	L6 AND calcium	627
<input type="checkbox"/>	L6	L5 AND GPCR	663
<input type="checkbox"/>	L5	435/325.CCLS.	15613
<input type="checkbox"/>	L4	Lin.IN.	44231
<input type="checkbox"/>	L3	Lin-D.IN.	402
<input type="checkbox"/>	L2	Lin-Dan.IN.	0
<input type="checkbox"/>	L1	(Lin-Daniel.IN.)	25

END OF SEARCH HISTORY



National  
Library  
of Medicine  
**NLM**

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Book
Search <b>PubMed</b>		<input type="text" value="for GPCR AND calcium AND citric acid"/>				<b>Go</b>	<b>Clear</b>		
		Limits	Preview/Index	History	Clipboard	Details			

About Entrez

Text Version

Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

**Display** **Summary** Show: **20** Sort **Send to** **Text**

Items 1-6 of 6

One page.

- 1:** Ricciardolo FL. Related Articles, Links  
**Mechanisms of citric acid-induced bronchoconstriction.**  
*Am J Med.* 2001 Dec 3;111 Suppl 8A:18S-24S. Review.  
 PMID: 11749919 [PubMed - indexed for MEDLINE]
- 2:** Zhang Y, Chou JH, Bradley J, Bargmann CI, Zinn K. Related Articles, Links  
**The Caenorhabditis elegans seven-transmembrane protein ODR-10 functions as an odorant receptor in mammalian cells.**  
*Proc Natl Acad Sci U S A.* 1997 Oct 28;94(22):12162-7.  
 PMID: 9342380 [PubMed - indexed for MEDLINE]
- 3:** Nederfors T, Dahlof C. Related Articles, Links  
**Effects on salivary flow rate and composition of withdrawal of and re-exposure to the beta 1-selective antagonist metoprolol in a hypertensive patient population.**  
*Eur J Oral Sci.* 1996 Jun;104(3):262-8.  
 PMID: 8831060 [PubMed - indexed for MEDLINE]
- 4:** Jensen JL, Xu T, Lamkin MS, Brodin P, Aars H, Berg T, Oppenheim FG. Related Articles, Links  
**Physiological regulation of the secretion of histatins and statherins in human parotid saliva.**  
*J Dent Res.* 1994 Dec;73(12):1811-7.  
 PMID: 7814752 [PubMed - indexed for MEDLINE]
- 5:** Bretschneider E, Glusa E, Schror K. Related Articles, Links  
**ADP-, PAF- and adrenaline-induced platelet aggregation and thromboxane formation are not affected by a thromboxane receptor antagonist at physiological external Ca<sup>++</sup> concentrations.**  
*Thromb Res.* 1994 Aug 1;75(3):233-42.  
 PMID: 7992234 [PubMed - indexed for MEDLINE]
- 6:** Hammerschmidt DE, Jeanneret C, Husak M, Lobell M, Jacob HS. Related Articles, Links  
**Lymphocyte aggregation in response to adrenergic stimulation.**  
*Blood.* 1988 May;71(5):1470-4.  
 PMID: 2896030 [PubMed - indexed for MEDLINE]

**Display** **Summary** Show: **20** Sort **Send to** **Text**

Write to the Help Desk

NCBI | NLM | NIH

Department of Health &amp; Human Services

Privacy Statement | Freedom of Information Act | Disclaimer



National  
Library  
of Medicine

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books	
Search <input type="text" value="PubMed"/> for <input type="text" value="Carninci AND Normalization"/>					<input type="button" value="Go"/>	<input type="button" value="Clear"/>				
		Limits	Preview/Index		History	Clipboard		Details		

About Entrez

[Text Version](#)

Entrez PubMed

Overview

[Help | FAQ](#)

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display  Summary Show:  Sort   Text

[One page.](#)

1: [Hirozane-Kishikawa T, Shiraki T, Waki K, Nakamura M, Arakawa T, Kawai J, Fagiolini M, Hensch TK, Hayashizaki Y, Carninci P.](#) Related Articles, Links

Subtraction of cap-trapped full-length cDNA libraries to select rare transcripts.

Biotechniques. 2003 Sep;35(3):510-6, 518.

PMID: 14513556 [PubMed - indexed for MEDLINE]

2: [Carninci P, Waki K, Shiraki T, Konno H, Shibata K, Itoh M, Aizawa K, Arakawa T, Ishii Y, Sasaki D, Bono H, Kondo S, Sugahara Y, Saito R, Osato N, Fukuda S, Sato K, Watahiki A, Hirozane-](#) Kishikawa T, Nakamura M, Shibata Y, Yasunishi A, Kikuchi N,

Yoshiki A, Kusakabe M, Gustincich S, Beisel K, Pavan W, Aidinis V, Nakagawara A, Held WA, Iwata H, Kono T, Nakauchi H, Lyons P, Wells C, Hume DA, Fagiolini M, Hensch TK, Brinkmeier M,

Camper S, Hirota J, Mombaerts P, Muramatsu M, Okazaki Y, Kawai J, Hayashizaki Y.

Targeting a complex transcriptome: the construction of the mouse full-length cDNA encyclopedia.

Genome Res. 2003 Jun;13(6B):1273-89.

PMID: 12819125 [PubMed - indexed for MEDLINE]

3: [Carninci P, Shibata Y, Hayatsu N, Sugahara Y, Shibata K, Itoh M, Konno H, Okazaki Y, Muramatsu M, Hayashizaki Y.](#) Related Articles, Links

Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes.

Genome Res. 2000 Oct;10(10):1617-30.

PMID: 11042159 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine



Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Book
Search	PubMed	<input checked="" type="checkbox"/>	for	Itoh AND 2000 AND Konno		<input type="button" value="Go"/>	<input type="button" value="Clear"/>		
		Limits	Preview/Index		History	Clipboard	Details		

About Entrez

Text Version

Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central


Display  Summary  Show: 20      
Items 1-6 of 6

One page

- 1: [Shibata K, Itoh M, Aizawa K, Nagaoka S, Sasaki N, Carninci P, Konno H, Akiyama J, Nishi K, Kitsunai T, Tashiro H, Itoh M, Sumi N, Ishii Y, Nakamura S, Hazema M, Nishine T, Harada A, Yamamoto R, Matsumoto H, Sakaguchi S, Ikegami T, Kashiwagi K, Fujikawa S, Inoue K, Togawa Y.](#) Related Articles, Links
- 2: [RIKEN integrated sequence analysis \(RISA\) system--384-format sequencing pipeline with 384 multicapillary sequencer.](#) Genome Res. 2000 Nov;10(11):1757-71.  
PMID: 11076861 [PubMed - indexed for MEDLINE]
- 3: [Carninci P, Shibata Y, Hayatsu N, Sugahara Y, Shibata K, Itoh M, Konno H, Okazaki Y, Muramatsu M, Hayashizaki Y.](#) Related Articles, Links
- 4: [Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes.](#) Genome Res. 2000 Oct;10(10):1617-30.  
PMID: 11042159 [PubMed - indexed for MEDLINE]
- 5: [Tomita F, Kohya T, Sakurai M, Kaji T, Yokoshiki H, Sato M, Sasaki K, Itoh Y, Konno M, Kitabatake A; Hokkaido Atrial Fibrillation Study Group.](#) Related Articles, Links
- 6: [Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20,000 cases in Japan.](#) Jpn Circ J. 2000 Sep;64(9):653-8.  
PMID: 10981848 [PubMed - indexed for MEDLINE]
- 7: [Adachi I, Morita K, Imran MB, Konno M, Mochizuki T, Kubo N, Itoh Y, Kato C, Tsukamoto E, Tamaki N.](#) Related Articles, Links
- 8: [Heterogeneity of myocardial wall motion and thickening in the left ventricle evaluated with quantitative gated SPECT.](#) J Nucl Cardiol. 2000 Jul-Aug;7(4):296-300.  
PMID: 10958270 [PubMed - indexed for MEDLINE]
- 9: [Itoh S, Yanagisawa T, Aoki S, Koba S, Iwata T, Ishioka H, Arata H, Mukae S, Geshi E, Konno N, Katagiri T, Utsumi H.](#) Related Articles, Links
- 10: [Generation of free radicals and the damage done to the sarcoplasmic reticulum during reperfusion injury following brief ischemia in the canine heart.](#) Jpn Circ J. 1999 May;63(5):373-8.  
PMID: 10943617 [PubMed - indexed for MEDLINE]
- 11: [Sato M, Ishida H, Konno K, Komatsuda T, Naganuma H, Watanabe S, Ohyama Y, Itoh M, Mukojima T, Sakai T.](#) Related Articles, Links
- 12: [Mesenteric panniculitis: sonographic findings.](#) Abdom Imaging. 2000 Mar-Apr;25(2):142-5.  
PMID: 10675455 [PubMed - indexed for MEDLINE]

Display  Summary  Show: 20

[Write to the Help Desk](#)



National  
Library  
of Medicine  
**NLM**

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Book
Search <b>PubMed</b>		<input checked="" type="checkbox"/>	for			<input type="button" value="Go"/>	<input type="button" value="Clear"/>		
		<a href="#">Limits</a>		<a href="#">Preview/Index</a>		<a href="#">History</a>		<a href="#">Clipboard</a>	<a href="#">Details</a>

[About Entrez](#)

[Text Version](#)

[Entrez PubMed](#)  
[Overview](#)  
[Help | FAQ](#)  
[Tutorial](#)  
[New/Noteworthy](#)  
[E-Utilities](#)

[PubMed Services](#)  
[Journals Database](#)  
[MeSH Database](#)  
[Single Citation Matcher](#)  
[Batch Citation Matcher](#)  
[Clinical Queries](#)  
[LinkOut](#)  
[Cubby](#)

[Related Resources](#)  
[Order Documents](#)  
[NLM Gateway](#)  
[TOXNET](#)  
[Consumer Health](#)  
[Clinical Alerts](#)  
[ClinicalTrials.gov](#)  
[PubMed Central](#)

[Display](#)  [Abstract](#)  Show: **20**  Sort    [Text](#)

[Related Articles](#), [Links](#)

1: [Genome Res. 2000 Nov;10\(11\):1757-71.](#)

FREE full text or title at  
[www.genome.org](http://www.genome.org)

## **RIKEN integrated sequence analysis (RISA) system—384-format sequencing pipeline with 384 multicapillary sequencer.**

**Shibata K, Itoh M, Aizawa K, Nagaoka S, Sasaki N, Carninci P, Konno H, Akiyama J, Nishi K, Kitsunai T, Tashiro H, Itoh M, Sumi N, Ishii Y, Nakamura S, Hazama M, Nishine T, Harada A, Yamamoto R, Matsumoto H, Sakaguchi S, Ikegami T, Kashiwagi K, Fujiwake S, Inoue K, Togawa Y.**

Genome Exploration Research Group, RIKEN, Genomic Sciences Center (GSC) and Genome Science Laboratory, RIKEN, Tsukuba Institute, Core Research of Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Ibaraki, Japan.

The RIKEN high-throughput 384-format sequencing pipeline (RISA system) including a 384-multicapillary sequencer (the so-called RISA sequencer) was developed for the RIKEN mouse encyclopedia project. The RISA system consists of colony picking, template preparation, sequencing reaction, and the sequencing process. A novel high-throughput 384-format capillary sequencer system (RISA sequencer system) was developed for the sequencing process. This system consists of a 384-multicapillary auto sequencer (RISA sequencer), a 384-multicapillary array assembler (CAS), and a 384-multicapillary casting device. The RISA sequencer can simultaneously analyze 384 independent sequencing products. The optical system is a scanning system chosen after careful comparison with an image detection system for the simultaneous detection of the 384-capillary array. This scanning system can be used with any fluorescent-labeled sequencing reaction (chain termination reaction), including transcriptional sequencing based on RNA polymerase, which was originally developed by us, and cycle sequencing based on thermostable DNA polymerase. For long-read sequencing, 380 out of 384 sequences (99.2%) were successfully analyzed and the average read length, with more than 99% accuracy, was 654.4 bp. A single RISA sequencer can analyze 216 kb with >99% accuracy in 2.7 h (90 kb/h). For short-read sequencing to cluster the 3' end and 5' end sequencing by reading 350 bp, 384 samples can be analyzed in 1.5 h. We have also developed a RISA inoculator, RISA filtrator and densitometer, RISA plasmid preparator which can handle throughput of 40,000 samples in 17.5 h, and a high-throughput RISA thermal cycler which has four 384-well sites. The combination of these technologies allowed us to construct the RISA system consisting of 16 RISA sequencers, which can process 50,000 DNA samples per day. One haploid genome shotgun sequence of a higher organism, such as

human, mouse, rat, domestic animals, and plants, can be revealed by seven RISA systems within one month.

PMID: 11076861 [PubMed - indexed for MEDLINE]

---

Show:

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



National  
Library  
of Medicine

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Book
Search	PubMed	<input checked="" type="checkbox"/>	for				<input type="button" value="Go"/>	<input type="button" value="Clear"/>	
		Limits		Preview/Index		History		Clipboard	
								Details	

About Entrez

[Text Version](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[Cubby](#)

Related Resources

[Order Documents](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

Display	Abstract	<input checked="" type="checkbox"/>	Show:	20	<input type="button" value="Sort"/>	<input type="button" value="Send to"/>	Text	<input type="button" value=""/>
---------	----------	-------------------------------------	-------	----	-------------------------------------	--	------	---------------------------------

**1: Genome Res. 2000 Oct;10(10):1617-30.**

[Related Articles](#), [Links](#)

Comment in:

- [Genome Res. 2000 Oct;10\(10\):1431-2.](#)

[FREE full text article at  
www.genome.org](#)

## Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes.

**Carninci P, Shibata Y, Hayatsu N, Sugahara Y, Shibata K, Itoh M, Konno H, Okazaki Y, Muramatsu M, Hayashizaki Y.**

Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center, Tsukuba, Japan. [rgscerg@rtc.riken.go.jp](mailto:rgscerg@rtc.riken.go.jp)

In the effort to prepare the mouse full-length cDNA encyclopedia, we previously developed several techniques to prepare and select full-length cDNAs. To increase the number of different cDNAs, we introduce here a strategy to prepare normalized and subtracted cDNA libraries in a single step. The method is based on hybridization of the first-strand, full-length cDNA with several RNA drivers, including starting mRNA as the normalizing driver and run-off transcripts from minilibraries containing highly expressed genes, rearranged clones, and previously sequenced cDNAs as subtracting drivers. Our method keeps the proportion of full-length cDNAs in the subtracted/normalized library high. Moreover, our method dramatically enhances the discovery of new genes as compared to results obtained by using standard, full-length cDNA libraries. This procedure can be extended to the preparation of full-length cDNA encyclopedias from other organisms.

PMID: 11042159 [PubMed - indexed for MEDLINE]

Display	Abstract	<input checked="" type="checkbox"/>	Show:	20	<input type="button" value="Sort"/>	<input type="button" value="Send to"/>	Text	<input type="button" value=""/>
---------	----------	-------------------------------------	-------	----	-------------------------------------	--	------	---------------------------------

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Connecting via Winsock to STN  
Welcome to STN International! Enter x:x  
\* \* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \* \*  
\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* STN Columbus \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:11:00 ON 26 AUG 2004

=> file BIOSCIENCE  
FILE 'ADISCTI' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 12:11:10 ON 26 AUG 2004

FILE 'AQUALINE' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT 2004 FAO (on behalf of the ASFA Advisory Board). All rights reserved

FILE 'BIOBUSINESS' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved.

FILE 'BIOENG' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 12:11:10 ON 26 AUG 2004

FILE 'CAPLUS' ENTERED AT 12:11:10 ON 26 AUG 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (c) 2004 DECHHEMA ev

FILE 'CEN' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 12:11:10 ON 26 AUG 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 12:11:10 ON 26 AUG 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 12:11:10 ON 26 AUG 2004

FILE 'FOMAD' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 12:11:10 ON 26 AUG 2004

FILE 'HEALSAFE' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 12:11:10 ON 26 AUG 2004

FILE 'NIOSHTIC' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 12:11:10 ON 26 AUG 2004

Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.

All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 12:11:10 ON 26 AUG 2004

Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 12:11:10 ON 26 AUG 2004

Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 12:11:10 ON 26 AUG 2004

Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT 2004 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 12:11:10 ON 26 AUG 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:11:10 ON 26 AUG 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S GPCR OR g-protein-coupled-receptor

6 FILES SEARCHED...

14 FILES SEARCHED...

25 FILES SEARCHED...

33 FILES SEARCHED...

49 FILES SEARCHED...

63 FILES SEARCHED...

L1 157620 GPCR OR G-PROTEIN-COUPLED-RECEPTOR

=> S L1 AND calcium

36 FILES SEARCHED...

L2 16298 L1 AND CALCIUM

=> S L2 AND citric acid

24 FILES SEARCHED...

25 FILES SEARCHED...

41 FILES SEARCHED...

63 FILES SEARCHED...

L3 1057 L2 AND CITRIC ACID

=> DUP REM L3

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'. ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
PROCESSING IS APPROXIMATELY 79% COMPLETE FOR L3  
PROCESSING COMPLETED FOR L3

L4 968 DUP REM L3 (89 DUPLICATES REMOVED)

=> S L4 AND PY<=2000

'2000' NOT A VALID FIELD CODE

6 FILES SEARCHED...

8 FILES SEARCHED...

12 FILES SEARCHED...

15 FILES SEARCHED...

20 FILES SEARCHED...

'2000' NOT A VALID FIELD CODE

29 FILES SEARCHED...

33 FILES SEARCHED...

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

43 FILES SEARCHED...

'2000' NOT A VALID FIELD CODE

47 FILES SEARCHED...

52 FILES SEARCHED...

'2000' NOT A VALID FIELD CODE

58 FILES SEARCHED...

'2000' NOT A VALID FIELD CODE

63 FILES SEARCHED...

67 FILES SEARCHED...

69 FILES SEARCHED...

L5 66 L4 AND PY<=2000

=> D L5 1-66

L5 ANSWER 1 OF 66 USPATFULL on STN

AN 2004:205782 USPATFULL

TI Receptor protein and method for diagnosing inflammatory diseases by using the same

IN Takahashi, Tsuneo, Tokyo, JAPAN

Ono, Mitsuharu, Shizuoka-Ken, JAPAN

Ishimaru, Hiroshi, Kanagawa-Ken, JAPAN

Kanno, Kimiyoshi, Shizuoka-Ken, JAPAN

Takahashi, Chiaki, Shizuoka-Ken, JAPAN

PA Asahi Kasei Kabushiki Kaisha, Osaka, JAPAN (non-U.S. corporation)

PI US 6777204 B1 20040817

WO 2000014229 20000316

<--

AI US 2001-786442 20010305 (9)

WO 1999-JP4801 19990903

PRAI JP 1998-249752 19980903

JP 1999-70800 19990316

DT Utility

FS GRANTED

LN.CNT 3082

INCL INCLM: 435/069.100  
 INCLS: 435/252.300; 435/320.100; 435/325.000; 435/471.000; 536/023.500;  
 530/300.000; 530/350.000  
 NCL NCLM: 435/069.100  
 NCLS: 435/252.300; 435/320.100; 435/325.000; 435/471.000; 536/023.500;  
 530/300.000; 530/350.000  
 IC [7]  
 ICM: C12P021-06  
 ICS: C07K001-00; A61K038-00; C12N015-74; C07H021-04  
 EXF 530/350; 530/300; 435/69.1; 435/252.3; 435/320.1; 435/325; 435/471;  
 435/761; 435/71.1; 435/71.2; 435/771; 536/23.5  
 L5 ANSWER 2 OF 66 USPATFULL on STN  
 AN 2004:79027 USPATFULL  
 TI .beta.2-adrenergic receptor agonists  
 IN Moran, Edmund J., San Francisco, CA, United States  
 Choi, Seok-Ki, Palo Alto, CA, United States  
 PA Theravance, Inc., South San Francisco, CA, United States (U.S.  
 corporation)  
 PI US 6713651 B1 20040330  
 WO 9964035 19991216  
 AI US 2000-674451 20001101 (9) <--  
 WO 1999-US11804 19990607  
 DT Utility  
 FS GRANTED  
 LN.CNT 3616  
 INCL INCLM: 564/372.000  
 INCLS: 548/326.000; 548/346.000; 548/440.000; 548/486.000; 548/490.000;  
 549/404.000; 424/001.110; 424/009.100; 424/178.100; 424/198.100;  
 435/007.100; 435/007.200; 436/501.000; 436/518.000; 564/347.000;  
 564/503.000; 544/062.000; 544/360.000; 544/363.000; 544/370.000;  
 544/372.000; 544/373.000; 544/380.000; 544/382.000; 546/156.000  
 NCL NCLM: 564/372.000  
 NCLS: 424/009.100; 424/178.100; 424/198.100; 435/007.100; 435/007.200;  
 436/501.000; 436/518.000; 514/255.030; 544/062.000; 544/360.000;  
 544/363.000; 544/370.000; 544/372.000; 544/373.000; 544/380.000;  
 544/382.000; 546/156.000; 548/326.100; 548/346.100; 548/440.000;  
 548/486.000; 548/490.000; 549/404.000; 564/347.000; 564/503.000  
 IC [7]  
 ICM: C07C211-00  
 ICS: C07C213-00; C07D401-00; C07D215-16; C07D209-82  
 EXF 424/1.11; 424/9.1; 424/178.1; 424/193.1; 435/7.1; 435/7.2; 436/501;  
 436/518; 564/372; 564/347; 564/503; 544/62; 544/360; 544/363; 544/370;  
 544/372; 544/373; 544/380; 544/382; 546/156; 548/326; 548/346; 548/440;  
 548/486; 548/490; 549/404  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 3 OF 66 USPATFULL on STN  
 AN 2004:53402 USPATFULL  
 TI Peptides that activate the \*\*\*G\*\*\* - \*\*\*protein\*\*\* \*\*\*coupled\*\*\*  
 \*\*\*receptor\*\*\* protein, OT7T175  
 IN Watanabe, Takuya, Osaka, JAPAN  
 Terao, Yasuko, Ibaraki, JAPAN  
 Shintani, Yasushi, Ibaraki, JAPAN  
 Ohtaki, Tetsuya, Ibaraki, JAPAN  
 Kanehashi, Kimiko, Ibaraki, JAPAN  
 Kitada, Chieko, Osaka, JAPAN  
 PA Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)  
 PI US 6699965 B1 20040302  
 WO 2000024890 20000504  
 AI US 2001-830428 20010426 (9)  
 WO 1999-JP5905 19991026  
 PRAI JP 1998-305949 19981027  
 JP 1999-27710 19990204  
 JP 1999-57207 19990304  
 JP 1999-276225 19990929  
 DT Utility  
 FS GRANTED  
 LN.CNT 3649  
 INCL INCLM: 530/300.000  
 INCLS: 530/326.000; 530/327.000; 530/328.000; 514/002.000; 514/014.000;  
 514/015.000; 514/016.000  
 NCL NCLM: 530/300.000  
 NCLS: 530/326.000; 530/327.000; 530/328.000  
 IC [7]  
 ICM: C07K014-00

EXF ICS: C07K007-00; A61K038-00; A61K038-04  
530/300; 530/327; 530/328; 530/326; 530/350; 514/2; 514/14; 514/15;  
514/16; 424/85.1; 424/184.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 66 USPATFULL on STN  
AN 2002:317435 USPATFULL  
TI C3A receptor ligands  
IN Lee, Dennis, San Mateo, CA, United States  
Bondinell, William E., Wayne, PA, United States  
Jurewicz, Anthony J., Royersford, PA, United States  
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S.  
corporation)  
PI US 6489339 B1 20021203  
WO 2000009129 20000224 <--  
AI US 2001-762459 20010207 (9)  
WO 1999-US18256 19990811  
PRAI US 1998-96055P 19980811 (60)  
DT Utility  
FS GRANTED  
LN.CNT 761  
INCL INCLM: 514/311.000  
INCLS: 514/563.000; 546/175.000; 562/439.000  
NCL NCLM: 514/311.000  
NCLS: 514/563.000; 546/175.000; 562/439.000  
IC [7]  
ICM: A61K031-47  
ICS: A61K031-198; A61P019-02; C07D215-20  
EXF 546/175; 562/439; 514/311  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 66 USPATFULL on STN  
AN 2002:268750 USPATFULL  
TI Azepine derivatives having effects on serotonin related systems  
IN Hauser, Kenneth Lee, Greencastle, IN, United States  
Hertel, Larry Wayne, Indianapolis, IN, United States  
PA Xu, Yao-Chang, Fishers, IN, United States  
Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 6465453 B1 20021015  
WO 2000000203 20000106 <--  
AI US 2000-701363 20001128 (9)  
WO 1999-US14778 19990629  
19990629 PCT 371 date  
PRAI US 1998-91245P 19980630 (60)  
DT Utility  
FS GRANTED  
LN.CNT 2882  
INCL INCLM: 514/217.030  
INCLS: 514/217.080; 540/596.000; 540/602.000  
NCL NCLM: 514/217.030  
NCLS: 514/217.080; 540/596.000; 540/602.000  
IC [7]  
ICM: A61K031-55  
ICS: A61P025-24; C07D403-00; C07D405-00; C07D409-00  
EXF 514/217.03; 514/217.08; 540/596; 540/602  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 66 USPATFULL on STN  
AN 2002:262381 USPATFULL  
TI Substituted .alpha., .beta.-anellated butyrolactones  
IN Stolle, Andreas, Milford, CT, United States  
Antonicek, Horst-Peter, Gladbach, GERMANY, FEDERAL REPUBLIC OF  
Lensky, Stephen, Kurten, GERMANY, FEDERAL REPUBLIC OF  
Voerste, Arnd, Koln, GERMANY, FEDERAL REPUBLIC OF  
Muller, Thomas, Bonn, GERMANY, FEDERAL REPUBLIC OF  
Baumgarten, Jorg, Wuppertal, GERMANY, FEDERAL REPUBLIC OF  
von dem Bruch, Karsten, Leverkusen, GERMANY, FEDERAL REPUBLIC OF  
Muller, Gerhard, Leverkusen, GERMANY, FEDERAL REPUBLIC OF  
Stropp, Udo, Haan, GERMANY, FEDERAL REPUBLIC OF  
Horvath, Ervin, Leverkusen, GERMANY, FEDERAL REPUBLIC OF  
de Vry, Jean-Marie-Viktor, Rosrath, GERMANY, FEDERAL REPUBLIC OF  
Schreiber, Rudy, Koln, GERMANY, FEDERAL REPUBLIC OF  
PA Bayer Aktiengesellschaft, Leverkusen, GERMANY, FEDERAL REPUBLIC OF  
(non-U.S. corporation)  
PI US 6462074 B1 20021008

AI WO 9936416 19990722 --  
US 2000-600355 20000714 (9)  
WO 1999-EP9800132 19990112  
20000714 PCT 371 date

PRAI DE 1998-19801646 19980117  
DT Utility  
FS GRANTED  
LN.CNT 2242

INCL INCLM: 514/432.000  
INCLS: 514/438.000; 514/470.000; 549/060.000; 549/305.000; 549/311.000;  
549/367.000; 549/432.000; 549/438.000

NCL NCLM: 514/432.000  
NCLS: 514/438.000; 514/470.000; 549/060.000; 549/305.000; 549/311.000;  
549/367.000; 549/432.000; 549/438.000

IC [7]  
ICM: A61K031-343  
ICS: A61K031-381; C07D307-93; C07D317-14; C07D323-00

EXF 514/470; 514/432; 514/438; 549/304; 549/60; 549/305; 549/311; 549/367;  
549/431

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 66 USPATFULL on STN  
AN 2002:209547 USPATFULL  
TI Piperidine derivatives having effects on serotonin related systems  
IN Hertel, Larry Wayne, Indianapolis, IN, United States  
Kohlman, Daniel Timothy, Camby, IN, United States  
Liang, Sidney Xi, Fishers, IN, United States  
Wong, David Taiwai, Indianapolis, IN, United States  
Xu, Yao-Chang, Fishers, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 6436964 B1 20020820  
WO 2000000198 20000106 --  
AI US 2000-701406 20001128 (9)  
WO 1999-US14732 19990629  
20001128 PCT 371 date

PRAI US 1998-91241P 19980630 (60)  
DT Utility  
FS GRANTED  
LN.CNT 3433  
INCL INCLM: 514/333.000  
INCLS: 546/256.000

NCL NCLM: 514/333.000  
NCLS: 546/256.000

IC [7]  
ICM: C07D405-06  
ICS: A61K031-444

EXF 546/256; 514/333

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 66 USPATFULL on STN  
AN 2002:202120 USPATFULL  
TI Substituted .beta., .gamma.-anellated lactones  
IN Stolle, Andreas, Milford, CT, United States  
Antonicek, Horst-Peter, Bergisch Gladbach, GERMANY, FEDERAL REPUBLIC OF  
Lensky, Stephen, Kurten, GERMANY, FEDERAL REPUBLIC OF  
Voerste, Arnd, Koln, GERMANY, FEDERAL REPUBLIC OF  
Muller, Thomas, Bonn-Beuel, GERMANY, FEDERAL REPUBLIC OF  
Baumgarten, Jorg, Wuppertal, GERMANY, FEDERAL REPUBLIC OF  
von dem Bruch, Karsten, Leverkusen, GERMANY, FEDERAL REPUBLIC OF  
Muller, Gerhard, Leverkusen, GERMANY, FEDERAL REPUBLIC OF  
Stropp, Udo, Haan, GERMANY, FEDERAL REPUBLIC OF  
Horvath, Ervin, Leverkusen, GERMANY, FEDERAL REPUBLIC OF  
de Vry, Jean-Marie-Viktor, Rosrath, GERMANY, FEDERAL REPUBLIC OF  
Schreiber, Rudy, Koln, GERMANY, FEDERAL REPUBLIC OF  
PA Bayer Aktiengesellschaft, Leverkusen, GERMANY, FEDERAL REPUBLIC OF  
(non-U.S. corporation)  
PI US 6433004 B1 20020813  
WO 9936417 19990722 --  
AI US 2000-600430 20000714 (9)  
WO 1999-EP22 19990105  
20000714 PCT 371 date

PRAI DE 1998-19801647 19980117  
DT Utility  
FS GRANTED  
LN.CNT 686

INCL INCLM: 514/443.000  
INCLS: 514/444.000; 514/468.000; 514/470.000; 549/058.000; 549/301.000;  
549/307.000; 549/312.000  
NCL NCLM: 514/443.000  
NCLS: 514/444.000; 514/468.000; 514/470.000; 549/058.000; 549/301.000;  
549/307.000; 549/312.000  
IC [7]  
ICM: A61K031-381  
ICS: C07D307-83; C07D307-935; C07D333-56; C07D407-04  
EXF 514/443; 514/444; 514/468; 514/470; 549/58; 549/301; 549/307; 549/312  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 66 USPATFULL on STN  
AN 2002:88520 USPATFULL  
TI Substituted bicyclic lactones  
IN Stolle, Andreas, Milford, CT, United States  
Antonicek, Horst-Peter, Bergisch Gladbach, GERMANY, FEDERAL REPUBLIC OF  
Lensky, Stephen, Kurten, GERMANY, FEDERAL REPUBLIC OF  
Voerste, Arnd, Koln, GERMANY, FEDERAL REPUBLIC OF  
Muller, Thomas, Bonn-Beuel, GERMANY, FEDERAL REPUBLIC OF  
Baumgarten, Jorg, Wuppertal, GERMANY, FEDERAL REPUBLIC OF  
von dem Bruch, Karsten, Leverkusen, GERMANY, FEDERAL REPUBLIC OF  
Muller, Gerhard, Leverkusen, GERMANY, FEDERAL REPUBLIC OF  
Stropp, Udo, Haan, GERMANY, FEDERAL REPUBLIC OF  
Horvath, Ervin, Leverkusen, GERMANY, FEDERAL REPUBLIC OF  
de Vry, Jean-Marie-Viktor, Rosrath, GERMANY, FEDERAL REPUBLIC OF  
Schreiber, Rudy, Koln, GERMANY, FEDERAL REPUBLIC OF  
PA Bayer Aktiengesellschaft, Leverkusen, GERMANY, FEDERAL REPUBLIC OF  
(non-U.S. corporation)  
PI US 6376539 B1 20020423  
WO 9936418 19990722 <--  
AI US 2000-600395 20000714 (9)  
WO 1999-EP31 19990107  
20000714 PCT 371 date  
PRAI DE 1998-19801636 19980117  
DT Utility  
FS GRANTED  
LN.CNT 2022  
INCL INCLM: 514/470.000  
INCLS: 514/444.000; 514/462.000; 549/060.000; 549/229.000; 549/295.000;  
549/297.000; 549/302.000; 549/304.000; 549/305.000  
NCL NCLM: 514/470.000  
NCLS: 514/444.000; 514/462.000; 549/060.000; 549/229.000; 549/295.000;  
549/297.000; 549/302.000; 549/304.000; 549/305.000  
IC [7]  
ICM: A61K031-34  
ICS: A61K031-335  
EXF 549/295; 549/60; 549/229; 549/302; 549/304; 549/305; 549/297; 514/444;  
514/462; 514/470  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 66 USPATFULL on STN  
AN 2002:45628 USPATFULL  
TI Pyrrolidine and pyrroline derivatives having effects on serotonin  
related systems  
IN Hertel, Larry Wayne, Indianapolis, IN, United States  
Xu, Yao-Chang, Fishers, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 6353008 B1 20020305  
WO 2000000196 20000106 <--  
AI US 2000-701361 20001128 (9)  
WO 1999-US14881 19990629  
20001128 PCT 371 date  
PRAI US 1998-91204P 19980630 (60)  
DT Utility  
FS GRANTED  
LN.CNT 2949  
INCL INCLM: 514/343.000  
INCLS: 514/414.000; 514/422.000; 546/276.400; 548/525.000; 548/466.000  
NCL NCLM: 514/343.000  
NCLS: 514/414.000; 514/422.000; 546/276.400; 548/466.000; 548/525.000  
IC [7]  
ICM: A61K031-44  
ICS: C07D405-02  
EXF 546/276.4; 548/525; 548/466; 514/343; 514/422; 514/414

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 66 USPATFULL on STN  
AN 2001:67795 USPATFULL  
TI Polypeptides their production and use  
IN Hinuma, Shuji, Tsukuba, Japan  
Habata, Yugo, Tsukuba, Japan  
Kawamata, Yuji, Tsukuba, Japan  
Hosoya, Masaki, Tsuchiura, Japan  
Fujii, Ryo, Tsukuba, Japan  
Fukusumi, Shojo, Tsukuba, Japan  
Kitada, Chieko, Sakai, Japan  
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)  
PI US 6228984 B1 20010508  
WO 9724436 19970710  
AI US 1997-776971 19970207 (8) <--  
WO 1996-JP3821 19961228  
19970206 PCT 371 date  
19970206 PCT 102(e) date  
PRAI JP 1995-343371 19951228  
JP 1996-59419 19960315  
JP 1996-211805 19960812  
JP 1996-246573 19960918  
DT Utility  
FS Granted  
LN.CNT 4756  
INCL INCLM: 530/300.000  
INCLS: 424/198.100; 435/069.400; 435/252.300; 514/012.000; 536/023.510  
NCL NCLM: 530/300.000  
NCLS: 424/198.100; 435/069.400; 435/252.300; 536/023.510  
IC [7]  
EXF ICM: C07K014-47  
ICS: C12N015-12; A61K038-17  
EXF 424/198.1; 435/252.3; 435/69.4; 514/12; 530/300; 536/23.51  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 66 USPATFULL on STN  
AN 2001:40474 USPATFULL  
TI Non-peptidyl vasopressin V1a antagonists  
IN Bruns, Jr., Robert F, Carmel, IN, United States  
Cooper, Robin DG, Indianapolis, IN, United States  
Dressman, Bruce A, Indianapolis, IN, United States  
Hunden, David C, Carmel, IN, United States  
Kaldor, Stephen W, Indianapolis, IN, United States  
Koppel, Gary A, Indianapolis, IN, United States  
Rizzo, John R, Indianapolis, IN, United States  
Skelton, Jeffrey J, Indianapolis, IN, United States  
Steinberg, Mitchell I, Indianapolis, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 6204260 B1 20010320  
WO 9730707 19970828 <--  
AI US 1999-125737 19990819 (9)  
WO 1997-US3039 19970220  
19990819 PCT 371 date  
19990819 PCT 102(e) date  
PRAI GB 1996-5044 19960309  
GB 1996-5045 19960309  
GB 1996-5046 19960309  
US 1996-12149P 19960223 (60)  
US 1996-12188P 19960223 (60)  
US 1996-12215P 19960223 (60)  
DT Utility  
FS Granted  
LN.CNT 3548  
INCL INCLM: 514/210.100  
INCLS: 540/200.000  
NCL NCLM: 514/210.100  
NCLS: 540/200.000  
IC [7]  
EXF ICM: A61K031-395  
ICS: C07D205-00  
EXF 540/200; 514/210  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 66 USPATFULL on STN

AN 2000:164488 USPATFULL  
TI Azole peptidomimetics as thrombin receptor antagonists  
IN Hoekstra, William, Villanova, PA, United States  
Hulshizer, Becky L., North Wales, PA, United States  
PA Ortho-McNeil Pharmaceuticals, Inc., Raritan, NJ, United States (U.S.  
corporation)  
PI US 6156732 20001205 <--  
AI US 1999-387489 19990901 (9)  
RLI Division of Ser. No. US 1999-245739, filed on 8 Feb 1999, now patented,  
Pat. No. US 6017890  
DT Utility  
FS Granted  
LN.CNT 696  
INCL INCLM: 514/018.000  
INCLS: 514/002.000; 514/017.000; 514/822.000  
NCL NCLM: 514/018.000  
NCLS: 514/002.000; 514/017.000; 514/822.000  
IC [7]  
ICM: A61K038-03  
ICS: A61K038-04; A61K038-07; A61K038-08  
EXF 514/2; 514/17; 514/18; 514/822  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 66 USPATFULL on STN  
AN 2000:150170 USPATFULL  
TI Alpha 1a adrenergic receptor antagonists  
IN Patane, Michael A., Harleysville, PA, United States  
Bock, Mark G., Hatfield, PA, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 6143750 20001107 <--  
AI US 1998-98780 19980617 (9)  
PRAI US 1997-50960P 19970618 (60)  
DT Utility  
FS Granted  
LN.CNT 2936  
INCL INCLM: 514/258.000  
INCLS: 514/258.000; 514/259.000; 514/274.000; 544/278.000; 544/280.000;  
544/295.000; 544/296.000; 544/316.000  
NCL NCLM: 514/255.050  
NCLS: 514/260.100; 514/265.100; 514/266.220; 514/274.000; 544/278.000;  
544/280.000; 544/295.000; 544/296.000; 544/316.000  
IC [7]  
ICM: A61K031-505  
ICS: A01N043-54; C07D491-00; C07D403-00; C07D239-02  
EXF 544/278; 544/280; 544/318; 544/295; 544/296; 544/316; 514/274; 514/258;  
514/259  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 66 USPATFULL on STN  
AN 2000:138332 USPATFULL  
TI Antisense oligonucleotide compositions and methods for the modulation of  
JNK proteins  
IN McKay, Robert, San Diego, CA, United States  
Dean, Nicholas, Olivenhain, CA, United States  
Monia, Brett P., La Costa, CA, United States  
Nero, Pamela S., Oceanside, CA, United States  
Gaarde, William A., Carlsbad, CA, United States  
PA Isis Pharmaceuticals Inc., Carlsbad, CA, United States (U.S.  
corporation)  
PI US 6133246 20001017 <--  
AI US 1999-287796 19990407 (9)  
RLI Continuation-in-part of Ser. No. US 1998-130616, filed on 7 Aug 1998  
which is a continuation-in-part of Ser. No. US 1997-910629, filed on 13  
Aug 1997, now patented, Pat. No. US 5877309  
DT Utility  
FS Granted  
LN.CNT 4754  
INCL INCLM: 514/044.000  
INCLS: 435/006.000; 435/183.000; 435/194.000; 435/325.000; 435/366.000;  
435/375.000; 536/023.100; 536/024.310; 536/024.500  
NCL NCLM: 514/044.000  
NCLS: 435/006.000; 435/183.000; 435/194.000; 435/325.000; 435/366.000;  
435/375.000; 536/023.100; 536/024.310; 536/024.500  
IC [7]  
ICM: A01K048-00  
ICS: C12N015-11; C12N015-85; C07H021-04

EXF 435/6; 435/69.1; 435/91.1; 435/440; 435/325; 435/352; 435/353; 435/354;  
435/366; 435/371; 435/375; 435/320.1; 435/183; 435/194; 536/23.1;  
536/24.3; 536/24.31; 536/24.33; 536/24.5; 514/44  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 66 USPATFULL on STN  
AN 2000:128363 USPATFULL  
TI Selective NPY (Y5) antagonists (tricyclics)  
IN Marzabadi, Mohammad R., Ridgewood, NJ, United States  
Wong, Wai C., Hamden, CT, United States  
Noble, Stewart A., Wheeling, IL, United States  
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S.  
corporation)  
PI US 6124331 20000926 <--  
AI US 1999-343994 19990630 (9)  
DT Utility  
FS Granted  
LN.CNT 2088  
INCL INCLM: 514/366.000  
INCLS: 514/375.000; 514/393.000; 548/218.000; 548/015.100; 548/302.100  
NCL NCLM: 514/366.000  
NCLS: 514/375.000; 514/393.000; 546/172.000; 548/151.000; 548/218.000;  
548/302.100  
IC [7]  
ICM: A61K031-425  
ICS: A61K031-42; C07D513-22; C07D498-00; C07D487-00  
EXF 548/151; 548/302.1; 548/218; 514/375; 514/366; 514/393  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 66 USPATFULL on STN  
AN 2000:117520 USPATFULL  
TI G-protein coupled receptor protein and a DNA encoding the receptor  
IN Hinuma, Shuji, Tsukuba, Japan  
Hosoya, Masaki, Tsuchiura, Japan  
Fujii, Ryo, Tsukuba, Japan  
Ohtaki, Tetsuya, Tsukuba, Japan  
Fukusumi, Shoji, Tsukuba, Japan  
Ohgi, Kazuhiro, Tsukuba, Japan  
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)  
PI US 6114139 20000905  
WO 9605302 19960222  
AI US 1995-513974 19950914 (8)  
WO 1995-JP1599 19950810  
19950914 PCT 371 date  
19950914 PCT 102(e) date  
PRAI JP 1994-189272 19940811  
JP 1994-189273 19940811  
JP 1994-189274 19940811  
JP 1994-236356 19940930  
JP 1994-236357 19940930  
JP 1994-270017 19941102  
JP 1994-326611 19941228  
JP 1995-7177 19950120  
JP 1995-57186 19950316  
JP 1995-93989 19950419  
DT Utility  
FS Granted  
LN.CNT 13008  
INCL INCLM: 435/069.100  
INCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100  
NCL NCLM: 435/069.100  
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
IC [7]  
ICM: C12N015-12  
ICS: C12N015-63; C12N005-10; C07K014-705  
EXF 536/23.5; 435/69.1; 435/325; 435/320.1; 530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 66 USPATFULL on STN  
AN 2000:102109 USPATFULL  
TI O-fucosyltransferase  
IN Wang, Yang, Milbrae, CA, United States  
Spellman, Michael W., Belmont, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
PI US 6100076 20000808 <--

AI US 1997-978741 19971126 (8)  
RLI Continuation-in-part of Ser. No. US 1997-792498, filed on 31 Jan 1997,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 3438  
INCL INCLM: 435/193.000  
NCL NCLM: 435/193.000  
IC [7]  
ICM: C12N009-10  
EXF 435/193  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 19 OF 66 USPATFULL on STN  
AN 2000:98448 USPATFULL  
TI .alpha..sub.1a adrenergic receptor antagonists  
IN Hofmann, Jacob M., Lansdale, PA, United States  
Chang, Raymond S. L., Lansdale, PA, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 6096763 20000801 <--  
AI US 1999-282743 19990331 (9)  
RLI Division of Ser. No. US 860314  
DT Utility  
FS Granted  
LN.CNT 2722  
INCL INCLM: 514/321.000  
INCLS: 514/322.000; 546/198.000; 546/199.000  
NCL NCLM: 514/321.000  
NCLS: 514/322.000; 546/198.000; 546/199.000  
IC [7]  
ICM: A61K031-445  
EXF 514/321; 514/322; 546/198; 546/199  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 20 OF 66 USPATFULL on STN  
AN 2000:84420 USPATFULL  
TI Human metabotropic glutamate receptor  
IN Stormann, Thomas M., Salt Lake City, UT, United States  
Simin, Rachel T., Salt Lake City, UT, United States  
Hammerland, Lance G., Bountiful, UT, United States  
Fuller, Forrest H., Salt Lake City, UT, United States  
PA NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.  
corporation)  
PI US 6084084 20000704 <--  
AI US 1996-604298 19960221 (8)  
DT Utility  
FS Granted  
LN.CNT 3237  
INCL INCLM: 536/023.500  
INCLS: 435/320.100; 435/325.000; 435/069.100  
NCL NCLM: 536/023.500  
NCLS: 435/069.100; 435/320.100; 435/325.000  
IC [7]  
ICM: C07H021-04  
ICL: C12P021-06; C12N005-00; C12N015-00  
EXF 536/23.1; 536/23.5; 435/320.1; 435/325; 435/69.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 66 USPATFULL on STN  
AN 2000:80768 USPATFULL  
TI Alpha 1A adrenergic receptor antagonists  
IN Patane, Michael A., Harleysville, PA, United States  
Bock, Mark G., Hatfield, PA, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 6080760 20000627 <--  
AI US 1998-98806 19980617 (9)  
PRAI US 1997-50137P 19970618 (60)  
DT Utility  
FS Granted  
LN.CNT 1855  
INCL INCLM: 514/326.000  
INCLS: 514/369.000; 514/376.000; 546/209.000; 548/188.000; 548/230.000  
NCL NCLM: 514/326.000  
NCLS: 514/369.000; 514/376.000; 546/209.000; 548/188.000; 548/230.000  
IC [7]  
ICM: A61K031-421

ICS: C07D211-32; C07D263-26  
EXF 514/326; 514/369; 514/376; 546/209; 548/188; 548/230  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 22 OF 66 USPATFULL on STN  
AN 2000:77191 USPATFULL  
TI Human metabotropic glutamate receptor  
IN Stormann, Thomas M., Salt Lake City, UT, United States  
Simin, Rachel T., Salt Lake City, UT, United States  
Hammerland, Lance G., Bountiful, UT, United States  
Fuller, Forrest H., Salt Lake City, UT, United States  
PA NPS Pharmaceuticals, Inc., salt Lake City, UT, United States (U.S.  
corporation)  
PI US 6077675 20000620 <--  
AI US 1997-823110 19970324 (8)  
RLI Division of Ser. No. US 1996-604298, filed on 21 Feb 1996  
DT Utility  
FS Granted  
LN.CNT 3286  
INCL INCLM: 435/007.100  
INCLS: 435/007.200; 435/069.100  
NCL NCLM: 435/007.100  
NCLS: 435/007.200; 435/069.100  
IC [7]  
ICM: G01N033-53  
EXF 435/7.1; 435/7.2; 435/6; 426/175  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 66 USPATFULL on STN  
AN 2000:74303 USPATFULL  
TI Alpha 1a adrenergic receptor antagonists  
IN Patane, Michael A., Harleysville, PA, United States  
Bock, Mark G., Hatfield, PA, United States  
Freidinger, Roger M., Lansdale, PA, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 6075038 20000613 <--  
WO 9640135 19961219 <--  
AI US 1997-973622 19971204 (8)  
WO 1996-US9363 19960604  
19971204 PCT 371 date  
19971204 PCT 102(e) date  
RLI Continuation-in-part of Ser. No. US 1995-488267, filed on 7 Jun 1995,  
now patented, Pat. No. US 5620993  
DT Utility  
FS Granted  
LN.CNT 1225  
INCL INCLM: 514/316.000  
INCLS: 514/326.000; 546/187.000; 546/189.000; 546/191.000  
NCL NCLM: 514/316.000  
NCLS: 514/326.000; 546/187.000; 546/189.000; 546/191.000  
IC [7]  
ICM: A61K031-445  
ICS: A61K031-4453; C07D211-06; C07D401-04  
EXF 546/193; 546/213; 546/215; 546/217; 546/219; 546/221; 546/228; 546/234;  
546/187; 546/189; 546/191  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 66 USPATFULL on STN  
AN 2000:54133 USPATFULL  
TI Alpha 1a adrenergic receptor antagonists  
IN Patane, Michael A., Harleysville, PA, United States  
Bock, Mark G., Hatfield, PA, United States  
Nagarathnam, Dhanapalan, Ramsey, NJ, United States  
Lagu, Bharat, Maywood, NJ, United States  
Wong, Wai C., Newark, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
Synaptic Pharmaceutical Corp., Paramus, NJ, United States (U.S.  
corporation)  
PI US 6057350 20000502 <--  
AI US 1998-98781 19980617 (9)  
PRAI US 1997-50136P 19970618 (60)  
DT Utility  
FS Granted  
LN.CNT 2143  
INCL INCLM: 514/376.000  
INCLS: 514/373.000; 514/523.000; 548/210.000; 548/211.000; 548/229.000;

NCL 548/230.000; 558/426.000  
NCLM: 514/376.000  
NCLS: 514/373.000; 514/523.000; 548/210.000; 548/211.000; 548/229.000;  
548/230.000; 558/426.000  
IC [7]  
ICM: A61K031-42  
ICS: A61K031-425; C07D263-22; C07D275-06  
EXF 548/229; 548/230; 514/376  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 25 OF 66 USPATFULL on STN  
AN 2000:50838 USPATFULL  
TI Heterocyclic vinyl ethers  
IN Adam, Geo, Schopfheim, Germany, Federal Republic of  
Kołczewski, Sabine, Lorrach, Germany, Federal Republic of  
Mutel, Vincent, Mulhouse, France  
Stadler, Heinz, Rheinfelden, Switzerland  
Wichmann, Jürgen, Steinen, Germany, Federal Republic of  
Woltering, Thomas Johannes, Weil am Rhein, Germany, Federal Republic of  
PA Hoffman-La Roche Inc., Nutley, NJ, United States (U.S. corporation)  
PI US 6054588 20000425 <--  
AI US 1999-304624 19990504 (9)  
RLI Division of Ser. No. US 1998-121737, filed on 23 Jul 1998  
PRAI EP 1997-114065 19970814  
DT Utility  
FS Granted  
LN.CNT 534  
INCL INCLM: 548/252.000  
NCL NCLM: 548/252.000  
IC [7]  
ICM: C07D257-04  
EXF 548/252  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 26 OF 66 USPATFULL on STN  
AN 2000:47345 USPATFULL  
TI Isolated human metabotropic glutamate receptor Mglur-8  
IN Stormann, Thomas M., Salt Lake City, UT, United States  
Simin, Rachel T., Salt Lake City, UT, United States  
Hammerland, Lance G., Bountiful, UT, United States  
Fuller, Forrest H., Salt Lake City, UT, United States  
PA NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.  
corporation)  
PI US 6051688 20000418 <--  
AI US 1997-823437 19970324 (8)  
RLI Division of Ser. No. US 1996-604298, filed on 21 Feb 1996  
DT Utility  
FS Granted  
LN.CNT 3301  
INCL INCLM: 530/350.000  
INCLS: 435/069.100; 536/023.500  
NCL NCLM: 530/350.000  
NCLS: 435/069.100; 536/023.500  
IC [7]  
ICM: C07K014-705  
ICS: C12N015-12  
EXF 435/69.1; 530/350; 576/23.5; 514/74  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 27 OF 66 USPATFULL on STN  
AN 2000:44099 USPATFULL  
TI Morpholine and thiomorpholine tachykinin receptor antagonists  
IN Dorn, Conrad P., Plainfield, NJ, United States  
Finke, Paul E., Milltown, NJ, United States  
Hale, Jeffrey J., Westfield, NJ, United States  
Maccoss, Malcolm, Freehold, NJ, United States  
Mills, Sander G., Woodbridge, NJ, United States  
Shah, Shrenik K., Metuchen, NJ, United States  
Chambers, Mark Stuart, Harts, United Kingdom  
Harrison, Timothy, Great Dunmow, United Kingdom  
Ladduwahetty, Tamara, Buckhurst Hill, United Kingdom  
Williams, Brian John, Great Dunnow, United Kingdom  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 6048859 20000411 <--  
AI US 1999-251190 19990216 (9)  
RLI Division of Ser. No. US 1997-959393, filed on 28 Oct 1997, now patented,

Pat. No. US 5872116 which is a division of Ser. No. US 1995-525259, filed on 8 Sep 1995, now patented, Pat. No. US 5719147 which is a continuation-in-part of Ser. No. WO 1994-US14497, filed on 13 Dec 1994 And Ser. No. US 1993-61194, filed on 19 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-971448, filed on 4 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992, now abandoned

DT Utility  
FS Granted  
LN.CNT 8151  
INCL INCLM: 514/227.500  
INCLS: 514/227.800; 514/231.200; 514/231.500; 514/241.000; 514/247.000;  
514/361.000; 514/362.000; 514/378.000; 514/385.000; 514/397.000;  
514/403.000; 514/404.000; 514/411.000; 514/872.000  
NCL NCLM: 514/227.500  
NCLS: 514/227.800; 514/231.200; 514/231.500; 514/241.000; 514/247.000;  
514/361.000; 514/362.000; 514/378.000; 514/385.000; 514/397.000;  
514/403.000; 514/404.000; 514/411.000; 514/872.000

IC [7] ICM: A61K031-54  
EXF ICS: A61K031-535; A61K031-53; A61K031-50; A61K031-41  
514/227.5; 514/227.8; 514/231.2; 514/231.5; 514/241; 514/247; 514/361;  
514/362; 514/378; 514/385; 514/397; 514/403; 514/404; 514/411; 514/872  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 28 OF 66 USPATFULL on STN  
AN 2000:43951 USPATFULL  
TI Human \*\*\*G\*\*\* - \*\*\*protein\*\*\*      \*\*\*coupled\*\*\*      \*\*\*receptor\*\*\*  
IN Hinuma, shuji, Ibaraki, Japan  
Fukusumi, Shoji, Ibaraki, Japan  
Kawamata, Yuji, Ibaraki, Japan  
PA Takeda Chemical Industries, Ltd., Tsukuba Ibaraki, Japan (non-U.S.  
corporation)  
PI US 6048711                          20000411                          <--  
AI US 1997-959381                          19971028 (8)  
PRAI JP 1996-286823                          19961029  
DT Utility  
FS Granted  
LN.CNT 2603  
INCL INCLM: 435/069.100  
INCLS: 536/023.500; 435/252.300; 435/254.110; 435/320.100; 435/325.000  
NCL NCLM: 435/069.100  
NCLS: 435/252.300; 435/254.110; 435/320.100; 435/325.000; 536/023.500  
IC [7]  
ICM: C12N015-09  
ICS: C07K014-705  
EXF 536/23.5; 435/69.1; 435/325; 435/252.3; 435/254.11; 435/320.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 29 OF 66 USPATFULL on STN  
AN 2000:31434 USPATFULL  
TI Administration of 5-HT<sub>sub</sub>.3 receptor antagonists to treat premature ejaculation  
IN Smith, William L., Oakland, CA, United States  
Doherty, Jr., Paul C., Cupertino, CA, United States  
Place, Virgil A., Kawaihae, HI, United States  
PA Vivus, Incorporated, Mountain View, CA, United States (U.S. corporation)  
PI US 6037360 20000314 <--  
AI US 1997-959061 19971028 (8)  
DT Utility  
FS Granted  
LN.CNT 920  
INCL INCLM: 514/397.000  
INCLS: 514/415.000  
NCL NCLM: 514/397.000  
NCLS: 514/415.000  
IC [7]  
ICM: A61K031-415  
ICS: A61K031-405  
EXF 514/415; 514/397  
CAS INDEXING IS AVAILABLE FOR THIS PATENT

L5 ANSWER 30 OF 66 USPATFULL on STN  
AN 2000:31428 USPATFULL  
TI Alpha 1a adrenergic receptor antagonists

IN Patane, Michael A., Harleysville, PA, United States  
Selnick, Harold G., Ambler, PA, United States  
Bock, Mark G., Hatfield, PA, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 6037354 20000314 <--  
AI US 1998-99031 19980617 (9)  
PRAI US 1997-49921P 19970618 (60)  
DT Utility  
FS Granted  
LN.CNT 4142  
INCL INCLM: 514/318.000  
INCLS: 514/326.000; 514/369.000; 514/376.000; 546/194.000; 546/209.000;  
548/228.000; 548/230.000; 548/183.000; 548/188.000; 548/189.000  
NCL NCLM: 514/318.000  
NCLS: 514/326.000; 514/369.000; 514/376.000; 546/194.000; 546/209.000;  
548/183.000; 548/188.000; 548/189.000; 548/228.000; 548/230.000  
IC [7]  
ICM: C07D263-06  
ICS: C07D263-04; C07D277-04; C07D413-12; A61K031-42  
EXF 548/228; 548/230; 548/231; 548/183; 548/188; 548/189; 514/318; 514/326;  
514/369; 514/376; 546/194; 546/209  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 31 OF 66 USPATFULL on STN  
AN 2000:31414 USPATFULL  
TI Synthesis and use of thiophene- and pyrrole-based heteroaromatic  
compounds  
IN Castelhano, Arlindo L., New City, NY, United States  
McKibben, Bryan, White Plains, NY, United States  
PA Cadus Pharmaceutical Corporation, Tarrytown, NY, United States (U.S.  
corporation)  
PI US 6037340 20000314 <--  
AI US 1997-864240 19970528 (8)  
DT Utility  
FS Granted  
LN.CNT 1896  
INCL INCLM: 514/183.000  
INCLS: 514/342.000; 514/422.000; 514/443.000; 514/447.000; 540/480.000;  
540/596.000; 546/280.400; 548/527.000; 548/950.000; 548/962.000;  
549/050.000; 549/068.000; 549/069.000  
NCL NCLM: 514/183.000  
NCLS: 514/342.000; 514/422.000; 514/443.000; 514/447.000; 540/480.000;  
540/596.000; 546/280.400; 548/527.000; 548/950.000; 548/962.000;  
549/050.000; 549/068.000; 549/069.000  
IC [7]  
ICM: A61K031-38  
ICS: A61K031-40; A61K031-435; C07D205-02  
EXF 514/443; 514/447; 549/68; 549/69; 549/50  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 32 OF 66 USPATFULL on STN  
AN 2000:24677 USPATFULL  
TI \*\*\*Calcium\*\*\* receptor-active molecules  
IN Nemeth, Edward F., Salt Lake City, UT, United States  
Van Wagenen, Bradford C., Salt Lake City, UT, United States  
Balandrin, Manuel F., Sandy, UT, United States  
DelMar, Eric G., Salt Lake City, UT, United States  
Moe, Scott T., Salt Lake City, UT, United States  
PA NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.  
corporation)  
The Brigham and Women's Hospital, Boston, MA, United States (U.S.  
corporation)  
PI US 6031003 20000229 <--  
AI US 1995-484719 19950607 (8)  
RLI Continuation-in-part of Ser. No. US 1994-353784, filed on 8 Dec 1994  
which is a continuation-in-part of Ser. No. WO 1994-US12117, filed on 21  
Oct 1994 Ser. No. Ser. No. US 1994-292827, filed on 19 Aug 1994, now  
abandoned Ser. No. Ser. No. US 1993-141248, filed on 22 Oct 1993, now  
abandoned And Ser. No. US 1993-9389, filed on 23 Feb 1993, now abandoned  
which is a continuation-in-part of Ser. No. US 1993-17127, filed on 12  
Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US  
1992-934161, filed on 21 Aug 1992, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-834044, filed on 11 Feb 1992,  
now abandoned which is a continuation-in-part of Ser. No. US  
1991-749451, filed on 23 Aug 1991, now abandoned  
DT Utility

FS Granted  
LN.CNT 8955  
INCL INCLM: 514/579.000  
INCLS: 514/614.000; 514/607.000; 514/646.000; 514/649.000  
NCL NCLM: 514/579.000  
NCLS: 514/607.000; 514/614.000; 514/646.000; 514/649.000  
IC [7]  
ICM: A61K031-44  
ICS: A61K031-135; A01N033-02; A01N037-18  
EXF 514/2; 514/614; 514/579; 514/607; 514/646; 514/649  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 33 OF 66 USPATFULL on STN  
AN 2000:9879 USPATFULL  
TI Azole peptidomimetics as thrombin receptor antagonists  
IN Hoekstra, William, Villanova, PA, United States  
Hulshizer, Becky L., North Wales, PA, United States  
PA Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, United States (U.S.  
corporation)  
PI US 6017890 20000125 <--  
AI US 1999-245739 19990208 (9)  
DT Utility  
FS Granted  
LN.CNT 742  
INCL INCLM: 514/019.000  
INCLS: 514/002.000; 514/018.000; 530/330.000; 530/331.000; 548/146.000;  
548/215.000; 548/333.500; 548/335.100  
NCL NCLM: 514/019.000  
NCLS: 514/002.000; 514/018.000; 530/330.000; 530/331.000; 548/146.000;  
548/215.000; 548/333.500; 548/335.100  
IC [6]  
ICM: A61K038-00  
ICS: C07K005-00  
EXF 514/2; 514/18-19; 530/300; 530/331; 548/146; 548/215; 548/333.5;  
548/335.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 34 OF 66 USPATFULL on STN  
AN 2000:1911 USPATFULL  
TI \*\*\*Calcium\*\*\* receptor-active molecules  
IN Nemeth, Edward F., Salt Lake City, UT, United States  
Van Wagenen, Bradford C., Salt Lake City, UT, United States  
Balandrin, Manuel F., Sandy, UT, United States  
DelMar, Eric G., Salt Lake City, UT, United States  
Moe, Scott T., Salt Lake City, UT, United States  
PA NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.  
corporation)  
The Brigham and Women's Hospital, Boston, MA, United States (U.S.  
corporation)  
PI US 6011068 20000104 <--  
AI US 1994-353784 19941208 (8)  
RLI Continuation-in-part of Ser. No. WO 1994-US12117, filed on 21 Oct 1994  
And a continuation-in-part of Ser. No. US 1994-292827, filed on 19 Aug  
1994, now abandoned And a continuation-in-part of Ser. No. US  
1993-141248, filed on 22 Oct 1993, now abandoned And a  
continuation-in-part of Ser. No. US 1993-9389, filed on 23 Feb 1993, now  
abandoned which is a continuation-in-part of Ser. No. US 1993-17127,  
filed on 12 Feb 1993, now abandoned which is a continuation-in-part of  
Ser. No. US 1992-934161, filed on 21 Aug 1992, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-834044, filed on 11 Feb 1992,  
now abandoned which is a continuation-in-part of Ser. No. US  
1991-749451, filed on 23 Aug 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 7466  
INCL INCLM: 514/654.000  
INCLS: 564/337.000; 564/366.000; 564/374.000; 564/384.000; 564/389.000  
NCL NCLM: 514/654.000  
NCLS: 564/337.000; 564/366.000; 564/374.000; 564/384.000; 564/389.000  
IC [6]  
ICM: A61K031-195  
ICS: C07C211-00; C07C213-00  
EXF 564/337; 564/366; 564/374; 564/384; 564/389; 514/654  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 35 OF 66 USPATFULL on STN

AN 1999:160238 USPATFULL  
TI 5-HT.sub.1F agonists intermediates  
IN Fillia, Sandra Ann, Indianapolis, IN, United States  
Johnson, Kirk W., Carmel, IN, United States  
Phebus, Lee A., Fountaintown, IN, United States  
Schaus, John Mehnert, Zionsville, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 5998622 19991207 <--  
AI US 1998-112562 19980709 (9)  
RLI Division of Ser. No. US 1997-969851, filed on 14 Nov 1997, now patented,  
Pat. No. US 5817671  
PRAI US 1996-30950P 19961115 (60)  
DT Utility  
FS Granted  
LN.CNT 2732  
INCL INCLM: 546/113.000  
INCLS: 544/127.000  
NCL NCLM: 546/113.000  
NCLS: 544/127.000  
IC [6]  
EXF ICM: C07D471-04  
EXF 546/113  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 36 OF 66 USPATFULL on STN  
AN 1999:141602 USPATFULL  
TI Chimeric receptors and methods for identifying compounds active at  
metabotropic glutamate receptors  
IN Fuller, Forrest H., La Jolla, CA, United States  
Krapcho, Karen J., Salt Lake City, UT, United States  
Hammerland, Lance G., Bountiful, UT, United States  
PA NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.  
corporation)  
PI US 5981195 19991109 <--  
AI US 1996-687289 19960725 (8)  
PRAI US 1995-1526P 19950726 (60)  
DT Utility  
FS Granted  
LN.CNT 4472  
INCL INCLM: 435/007.100  
INCLS: 435/007.200; 435/069.700; 435/252.300; 435/320.100; 530/350.000;  
536/023.400  
NCL NCLM: 435/007.100  
NCLS: 435/007.200; 435/069.700; 435/252.300; 435/320.100; 530/350.000;  
536/023.400  
IC [6]  
EXF ICM: C07K019-00  
ICS: C12N015-62  
EXF 435/69.7; 435/6; 435/7.1; 435/7.2; 435/252.3; 435/32.7; 530/350;  
536/23.4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 37 OF 66 USPATFULL on STN  
AN 1999:137264 USPATFULL  
TI Alpha 1a adrenergic receptor antagonists  
IN Patane, Michael A., Harleysville, PA, United States  
Bock, Mark G., Hatfield, PA, United States  
Freidinger, Roger M., Lansdale, PA, United States  
Ponticello, Rose Ann, Harleysville, PA, United States  
Newton, Randall C., West Point, PA, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5977115 19991102 <--  
WO 9640136 19961219 <--  
AI US 1997-973624 19971204 (8)  
WO 1996-US9425 19960606  
19971204 PCT 371 date  
19971204 PCT 102(e) date  
RLI Continuation-in-part of Ser. No. US 1995-488272, filed on 7 Jun 1995,  
now patented, Pat. No. US 5403874  
DT Utility  
FS Granted  
LN.CNT 2740  
INCL INCLM: 514/255.000  
INCLS: 544/358.000; 544/360.000; 544/366.000; 544/367.000; 544/372.000;  
544/392.000; 544/393.000; 544/396.000; 544/400.000; 544/405.000

NCL NCLM: 514/252.110  
NCLS: 514/235.800; 514/252.130; 514/253.010; 514/253.090; 514/254.010;  
514/254.100; 514/255.030; 544/358.000; 544/360.000; 544/366.000;  
544/367.000; 544/372.000; 544/392.000; 544/393.000; 544/396.000;  
544/400.000; 544/405.000

IC [6]  
ICM: A61K031-495  
ICS: C07D295-12

EXF 544/358; 544/360; 544/366; 544/367; 544/372; 544/392; 544/393; 544/396;  
544/400; 544/405; 514/255

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 38 OF 66 USPATFULL on STN  
AN 1999:132773 USPATFULL  
TI Methods of treating nueropeptide Y-associated conditions  
IN Bue-Valleskey, Julianne Maude, Indianapolis, IN, United States  
Heiman, Mark Louis, Indianapolis, IN, United States  
Stephens, Thomas Wesley, Indianapolis, IN, United States  
Tinsley, Frank C., Indianapolis, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 5972888 19991026 <--  
AI US 1997-959112 19971023 (8)  
RLI Continuation of Ser. No. US 1996-672897, filed on 28 Jun 1996, now  
abandoned  
PRAI US 1995-737P 19950630 (60)  
US 1995-861P 19950630 (60)  
DT Utility  
FS Granted  
LN.CNT 3222  
INCL INCLM: 514/012.000  
INCLS: 530/324.000; 546/202.000  
NCL NCLM: 514/012.000  
NCLS: 530/324.000; 546/202.000  
IC [6]  
ICM: A61K038-00  
ICS: C07K014-00  
EXF 514/12; 514/324; 514/909; 546/202; 530/324; 530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 39 OF 66 USPATFULL on STN  
AN 1999:121216 USPATFULL  
TI \*\*\*Calcium\*\*\* receptor-active molecules  
IN Brown, Edward M., Milton, MA, United States  
Hebert, Steven C., Wellesley, MA, United States  
Garrett, Jr., James E., Salt Lake City, UT, United States  
PA NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.  
corporation)  
Brigham and Women's Hospital, Boston, MA, United States (U.S.  
corporation)  
PI US 5962314 19991005 <--  
AI US 1997-943986 19971003 (8)  
RLI Continuation of Ser. No. US 1995-484565, filed on 7 Jun 1995, now  
patented, Pat. No. US 5763569 which is a continuation-in-part of Ser.  
No. US 1994-353784, filed on 8 Dec 1994 which is a continuation-in-part  
of Ser. No. WO 1994-US12117, filed on 21 Oct 1994 Ser. No. Ser. No. US  
1994-292827, filed on 19 Aug 1994, now abandoned Ser. No. Ser. No. US  
1993-141248, filed on 22 Oct 1993, now abandoned And Ser. No. US  
1993-9389, filed on 23 Feb 1993, now abandoned  
DT Utility  
FS Granted  
LN.CNT 7882  
INCL INCLM: 435/320.100  
INCLS: 435/325.000; 435/243.000; 435/252.300; 536/023.100; 536/023.400;  
536/023.500; 536/024.310; 530/300.000; 530/326.000; 530/350.000  
NCL NCLM: 435/320.100  
NCLS: 435/243.000; 435/252.300; 435/325.000; 530/300.000; 530/326.000;  
530/350.000; 536/023.100; 536/023.400; 536/023.500; 536/024.310  
IC [6]  
ICM: C12N015-63  
ICS: C12N015-11; C12N015-12; C07K007-00  
EXF 435/69.1; 435/252.3; 435/320.1; 435/325; 435/243; 536/23.1; 536/23.4;  
536/23.5; 536/24.31; 530/300; 530/326; 530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 40 OF 66 USPATFULL on STN

AN 1999:117502 USPATFULL  
TI Phenyl-substituted 5H-thiazolo[3,2-A]pyrimidine derivative glutamate  
receptor antagonists  
IN Adam, Geo, Schopfheim, Germany, Federal Republic of  
Kolczewski, Sabine, Lorrach, Germany, Federal Republic of  
Mutel, Vincent, Mulhouse, France  
Wichmann, Jurgen, Steinen, Germany, Federal Republic of  
Woltering, Thomas Johannes, Weil am Rhein, Germany, Federal Republic of  
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation) <--  
PI US 5958931 19990928  
AI US 1998-115191 19980714 (9)  
PRAI EP 1997-112324 19970718  
DT Utility  
FS Granted  
LN.CNT 816  
INCL INCLM: 514/258.000  
INCLS: 544/278.000  
NCL NCLM: 514/259.200  
NCLS: 544/278.000  
IC [6]  
ICM: A61K031-505  
ICS: C07D513-04  
EXF 514/258; 544/278; 544/282  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 41 OF 66 USPATFULL on STN  
AN 1999:117455 USPATFULL  
TI Compositions and methods for treating erectile dysfunction  
IN Kifor, Imre, Methuen, MA, United States  
Williams, Gordon, Belmont, MA, United States  
PA The Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)  
PI US 5958884 19990928 <--  
AI US 1998-47594 19980325 (9)  
PRAI US 1997-41875P 19970411 (60)  
DT Utility  
FS Granted  
LN.CNT 692  
INCL INCLM: 514/016.000  
INCLS: 514/048.000; 514/381.000; 514/396.000; 514/397.000; 514/400.000  
NCL NCLM: 514/016.000  
NCLS: 514/048.000; 514/381.000; 514/396.000; 514/397.000; 514/400.000  
IC [6]  
ICM: A61K031-41  
ICS: A61K031-70; A61K038-08  
EXF 514/16; 514/48; 514/381; 514/396; 514/397; 514/400; 530/316; 548/252;  
548/253; 548/312.7; 548/323.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 42 OF 66 USPATFULL on STN  
AN 1999:110340 USPATFULL  
TI Alpha 1a adrenergic receptor antagonists  
IN Evans, Ben E., Lansdale, PA, United States  
Ponticello, Gerald S., Lansdale, PA, United States  
Hoffman, Jacob M., Lansdale, PA, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5952351 19990914 <--  
WO 9625934 19960829 <--  
AI US 1997-860314 19970813 (8)  
WO 1996-US2534 19960223  
19970813 PCT 371 date  
19970813 PCT 102(e) date  
RLI Continuation-in-part of Ser. No. US 1995-392699, filed on 23 Feb 1995,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 2602  
INCL INCLM: 514/321.000  
INCLS: 514/322.000; 546/198.000; 546/199.000  
NCL NCLM: 514/321.000  
NCLS: 514/322.000; 546/198.000; 546/199.000  
IC [6]  
ICM: A61K031-445  
ICS: C07D413-14  
EXF 514/321; 514/322; 546/198; 546/199  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 43 OF 66 USPATFULL on STN  
AN 1999:78727 USPATFULL  
TI Alpha 1a adrenergic receptor antagonists  
IN Bock, Mark G., Hatfield, PA, United States  
Patane, Michael A., Harleysville, PA, United States  
Ponticello, Rose Ann, Madison, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5922722 19990713 <--  
WO 9717967 19970522 <--  
AI US 1998-66477 19980422 (9)  
WO 1996-US18321 19961112  
19980422 PCT 371 date  
19980422 PCT 102(e) date  
DT Utility  
FS Granted  
LN.CNT 1397  
INCL INCLM: 514/255.000  
INCLS: 514/318.000  
NCL NCLM: 514/253.010  
NCLS: 514/255.010; 514/255.020; 514/255.030; 514/318.000  
IC [6]  
ICM: A61K031-445  
EXF 514/255; 514/318  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 44 OF 66 USPATFULL on STN  
AN 1999:78711 USPATFULL  
TI Morpholine and thiomorpholine tachykinin receptor antagonists  
IN Dorn, Conrad P., Plainfield, NJ, United States  
Hale, Jeffrey J., Westfield, NJ, United States  
Maccoss, Malcolm, Freehold, NJ, United States  
Mills, Sander G., Woodbridge, NJ, United States  
Shah, Shrenik K., Metuchen, NJ, United States  
Ladduwahetty, Tamara, Buckhurst Hill, United Kingdom  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5922706 19990713 <--  
AI US 1997-969685 19971113 (8)  
RLI Division of Ser. No. US 1995-525259, filed on 5 Sep 1995, now patented,  
Pat. No. US 5719147 which is a continuation-in-part of Ser. No. WO  
1994-US14497, filed on 13 Dec 1994 And Ser. No. US 1993-169889, filed on  
17 Dec 1993, now abandoned which is a continuation-in-part of Ser. No.  
US 1993-61914, filed on 19 May 1993, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-971448, filed on 4 Nov 1992,  
now abandoned which is a continuation-in-part of Ser. No. US  
1992-905976, filed on 29 Jun 1992, now abandoned  
DT Utility  
FS Granted  
LN.CNT 7932  
INCL INCLM: 514/227.500  
INCLS: 514/227.800; 514/228.200; 514/231.200; 514/231.500; 514/233.500;  
514/233.800; 514/235.200; 514/235.800; 514/236.200; 514/236.500;  
514/236.800; 514/237.200; 544/059.000; 544/060.000; 544/062.000;  
544/058.100; 544/058.400; 544/106.000; 544/111.000; 544/114.000;  
544/122.000; 544/128.000; 544/129.000; 544/132.000; 544/133.000;  
544/137.000; 544/139.000; 544/140.000; 544/141.000; 544/143.000;  
544/145.000; 544/146.000; 544/148.000; 544/152.000; 544/153.000  
NCL NCLM: 514/227.500  
NCLS: 514/227.800; 514/228.200; 514/231.200; 514/231.500; 514/233.500;  
514/233.800; 514/235.200; 514/235.800; 514/236.200; 514/236.500;  
514/236.800; 514/237.200; 544/058.100; 544/058.400; 544/059.000;  
544/060.000; 544/062.000; 544/106.000; 544/111.000; 544/114.000;  
544/122.000; 544/128.000; 544/129.000; 544/132.000; 544/133.000;  
544/137.000; 544/139.000; 544/140.000; 544/141.000; 544/143.000;  
544/145.000; 544/146.000; 544/148.000; 544/152.000; 544/153.000  
IC [6]  
ICM: C07D413-04  
ICS: C07D417-04; C07D279-12; C07D265-30; A61K031-54; A61K031-535  
EXF 544/59-62; 544/58.1; 544/58.4; 544/106; 544/111; 544/114; 544/122;  
544/128-153; 514/227.5; 514/227.8; 514/228.2; 514/228.5; 514/236.2;  
514/236.5; 514/233.8; 514/233.5; 514/231.2; 514/231.5; 514/236.8;  
514/235.8; 514/237.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 45 OF 66 USPATFULL on STN  
AN 1999:75792 USPATFULL

TI Nitropyridine compound  
IN Filla, Sandra Ann, Indianapolis, IN, United States  
Johnson, Kirk W., Carmel, IN, United States  
Phebus, Lee A., Fountaintown, IN, United States  
Schaus, John Mehnert, Zionsville, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 5919936 19990706 <--  
AI US 1998-112560 19980709 (9)  
RLI Division of Ser. No. US 1997-969851, filed on 14 Nov 1997  
PRAI US 1996-30950P 19961115 (60)  
DT Utility  
FS Granted  
LN.CNT 2734  
INCL INCLM: 546/308.000  
NCL NCLM: 546/308.000  
IC [6]  
ICM: C07D213-76  
EXF 546/308  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 46 OF 66 USPATFULL on STN  
AN 1999:59074 USPATFULL  
TI 5-HT.sub.1F -agonists effective in treating migraine  
IN Filla, Sandra A., Franklin, IN, United States  
Mathes, Brian M., Indianapolis, IN, United States  
Schaus, John M., Zionsville, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 5905084 19990518 <--  
AI US 1997-970637 19971114 (8)  
DT Utility  
FS Granted  
LN.CNT 1541  
INCL INCLM: 514/300.000  
INCLS: 546/113.000  
NCL NCLM: 514/300.000  
NCLS: 546/113.000  
IC [6]  
ICM: A61K031-44  
ICS: C07D047-02  
EXF 514/300; 546/113  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 47 OF 66 USPATFULL on STN  
AN 1999:27762 USPATFULL  
TI Antisense oligonucleotides against JNK  
IN McKay, Robert, La Mesa, CA, United States  
Dean, Nicholas M., Encinitas, CA, United States  
PA ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S.  
corporation)  
PI US 5877309 19990302 <--  
AI US 1997-910629 19970813 (8)  
DT Utility  
FS Granted  
LN.CNT 3556  
INCL INCLM: 536/024.500  
INCLS: 435/006.000; 435/091.100; 435/172.100; 435/371.000; 435/375.000;  
536/023.100; 536/024.300; 536/024.500  
NCL NCLM: 536/024.500  
NCLS: 435/006.000; 435/091.100; 435/371.000; 435/375.000; 536/023.100;  
536/024.300  
IC [6]  
ICM: C07H021-04  
ICS: C12Q001-68; C12N015-85  
EXF 536/24.5; 536/24.3; 536/23.2; 536/23.1; 514/44; 435/320.1; 435/371;  
435/16; 435/375; 435/91.1; 435/172.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 48 OF 66 USPATFULL on STN  
AN 1999:22097 USPATFULL  
TI Morpholine and thiomorpholine tachykinin receptor antagonists  
IN Dorn, Conrad P., Plainfield, NJ, United States  
Finke, Paul E., Milltown, NJ, United States  
Hale, Jeffrey J., Westfield, NJ, United States  
Maccoss, Malcolm, Freehold, NJ, United States

Mills, Sander G., Woodbridge, NJ, United States  
 Shah, Shrenik K., Metuchen, NJ, United States  
 Chambers, Mark Stuart, Watford, England  
 Harrison, Timothy, Great Dunmow, England  
 Ladduwahetty, Tamara, Buckhurst Hill, England  
 Williams, Brian John, Great Dunnow, England  
 PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
 PI US 5872116 19990216 <--  
 AI US 1997-959393 19971028 (8)  
 RLI Division of Ser. No. US 1995-525259, filed on 8 Sep 1995, now patented,  
     Pat. No. US 5719147 And a continuation-in-part of Ser. No. US  
     1993-169889, filed on 17 Dec 1993, now abandoned which is a  
     continuation-in-part of Ser. No. US 1993-61914, filed on 19 May 1993,  
     now abandoned which is a continuation-in-part of Ser. No. US  
     1992-971448, filed on 4 Nov 1992, now abandoned which is a  
     continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992,  
     now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 8249  
 INCL INCLM: 514/227.500  
       INCLS: 514/227.800; 514/231.200; 514/231.500; 514/241.000; 514/247.000;  
           514/361.000; 514/362.000; 514/363.000; 514/378.000; 514/397.000;  
           514/825.000  
 NCL NCLM: 514/227.500  
       NCLS: 514/227.800; 514/231.200; 514/231.500; 514/241.000; 514/247.000;  
           514/361.000; 514/362.000; 514/363.000; 514/378.000; 514/397.000;  
           514/825.000  
 IC [6]  
     ICM: A61K031-54  
     ICS: A61K031-535; A61K031-53; A61K031-50  
 EXF 514/227.5; 514/227.8; 514/231.2; 514/231.5; 514/241; 514/247; 514/361;  
       514/362; 514/363; 514/378; 514/397; 514/825  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 49 OF 66 USPATFULL on STN  
 AN 1999:4350 USPATFULL  
 TI Method of screening \*\*\*calcium\*\*\* receptor-active molecules  
 IN Nemeth, Edward F., Salt Lake City, UT, United States  
     Brown, Edward M., Milton, MA, United States  
     Hebert, Steven C., Wellesley, MA, United States  
     Garrett, Jr., James E., Salt Lake City, UT, United States  
     Van Wagenen, Bradford C., Salt Lake City, UT, United States  
     Balandrin, Manuel F., Sandy, UT, United States  
     Del Mar, Eric G., Salt Lake City, UT, United States  
 PA The Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S.  
     corporation)  
     NPS Pharmaceuticals, Inc., Salt Lake City, UT, United states (U.S.  
     corporation)  
 PI US 5858684 19990112 <--  
 AI US 1995-480751 19950607 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-353784, filed on 8 Dec 1994  
     which is a continuation-in-part of Ser. No. US 1994-292827, filed on 19  
     Aug 1994, now abandoned And a continuation-in-part of Ser. No. US  
     1993-141248, filed on 22 Oct 1993, now abandoned And a  
     continuation-in-part of ser. No. US 1993-9389, filed on 23 Feb 1993, now  
     abandoned which is a continuation-in-part of Ser. No. US 1993-17127,  
     filed on 12 Feb 1993, now abandoned which is a continuation-in-part of  
     Ser. No. US 1992-934161, filed on 21 Aug 1992, now abandoned which is a  
     continuation-in-part of ser. No. US 1992-834044, filed on 11 Feb 1992,  
     now abandoned which is a continuation-in-part of Ser. No. US  
     1991-749451, filed on 23 Aug 1991, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 7588  
 INCL INCLM: 435/007.200  
       INCLS: 435/065.100; 435/325.000; 435/252.300; 435/320.100; 435/007.100;  
           530/300.000; 530/324.000; 530/350.000; 536/023.100; 536/023.500  
 NCL NCLM: 435/007.200  
       NCLS: 435/007.100; 435/069.100; 435/252.300; 435/320.100; 435/325.000;  
           530/300.000; 530/324.000; 530/350.000; 536/023.100; 536/023.500  
 IC [6]  
     ICM: C12Q001-68  
 EXF 435/7.2; 435/65.1; 435/325; 435/252.3; 435/320.1; 530/300; 530/350;  
       530/324; 536/23.1; 536/23.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 50 OF 66 USPATFULL on STN  
AN 1998:122422 USPATFULL  
TI 5-HT.sub.1F agonists  
IN Filla, Sandra Ann, Indianapolis, IN, United States  
Johnson, Kirk W., Carmel, IN, United States  
Phebus, Lee A., Fountaintown, IN, United States  
Schaus, John Mehnert, Zionsville, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 5817671 19981006 <--  
AI US 1997-969851 19971114 (8)  
PRAI US 1996-30950P 19961115 (60)  
DT Utility  
FS Granted  
LN.CNT 2947  
INCL INCLM: 514/300.000  
INCLS: 544/058.400; 544/127.000; 546/113.000  
NCL NCLM: 514/300.000  
NCLS: 544/058.400; 544/127.000; 546/113.000  
IC [6]  
ICM: A61K031-44  
ICS: C07D471-04  
EXF 546/113; 514/300  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 51 OF 66 USPATFULL on STN  
AN 1998:111936 USPATFULL  
TI Alpha 1a adrenergic receptor antagonist  
IN Bock, Marg G., Hatfield, PA, United States  
Patake, Michael A., Harleysville, PA, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5807856 19980915 <--  
AI US 1996-747687 19961112 (8)  
PRAI US 1995-7964P 19951115 (60)  
DT Utility  
FS Granted  
LN.CNT 1306  
INCL INCLM: 514/252.000  
INCLS: 514/171.000; 514/253.000; 514/255.000; 544/360.000; 544/364.000;  
544/368.000; 544/379.000; 544/393.000; 544/388.000; 544/389.000;  
544/390.000; 544/384.000; 544/385.000  
NCL NCLM: 514/252.130  
NCLS: 514/171.000; 514/253.010; 514/253.120; 514/254.100; 514/255.010;  
514/255.020; 514/255.030; 544/360.000; 544/364.000; 544/368.000;  
544/379.000; 544/384.000; 544/385.000; 544/388.000; 544/389.000;  
544/390.000; 544/393.000  
IC [6]  
ICM: A61K031-495  
ICS: A61K031-58; C07D241-04; C07D417-06  
EXF 544/393; 544/360; 544/379; 544/364; 544/384-385; 544/388-390; 514/255;  
514/252; 514/171  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 52 OF 66 USPATFULL on STN  
AN 1998:82768 USPATFULL  
TI Method for inhibiting activation of the human A3 adenosine receptor to  
treat asthma  
IN Jacobson, Marlene A., Elkins Park, PA, United States  
Norton, Richard, Somerset, NJ, United States  
Chakravarty, Prasun K., Edison, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5780481 19980714 <--  
AI US 1996-694061 19960808 (8)  
DT Utility  
FS Granted  
LN.CNT 912  
INCL INCLM: 514/293.000  
INCLS: 514/294.000; 514/359.000; 514/461.000  
NCL NCLM: 514/293.000  
NCLS: 514/294.000; 514/359.000; 514/461.000  
IC [6]  
ICM: A61K031-44  
ICS: A61K031-41; A61K031-34  
EXF 514/293; 514/294; 514/359; 514/461  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 53 OF 66 USPATFULL on STN  
AN 1998:82754 USPATFULL  
TI Morpholine compounds are prodrugs useful as tachykinin receptor antagonists  
IN Dorn, Conrad P., Plainfield, NJ, United States  
Hale, Jeffrey J., Westfield, NJ, United States  
Maccoss, Malcolm, Freehold, NJ, United States  
Mills, Sander G., Woodbridge, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5780467 19980714 <--  
AI US 1997-907738 19970808 (8)  
RLI Division of Ser. No. US 1995-525870, filed on 8 Sep 1995, now patented,  
Pat. No. US 5691336 which is a continuation-in-part of Ser. No. US  
1994-206771, filed on 4 Mar 1994, now abandoned  
DT Utility  
FS Granted  
LN.CNT 7260  
INCL INCLM: 514/236.200  
INCLS: 514/233.500; 514/235.200; 514/235.500; 514/235.800  
NCL NCLM: 514/236.200  
NCLS: 514/233.500; 514/235.200; 514/235.500; 514/235.800  
IC [6]  
ICM: A61K031-535  
EXF 514/235.2; 514/235.5; 514/235.8; 514/233.5; 514/236.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 54 OF 66 USPATFULL on STN  
AN 1998:79171 USPATFULL  
TI Naphthimidazolyl neuropeptide Y receptor antagonists  
IN Nunes, Anne Marie, Andover, MA, United States  
Zarrinmayeh, Hamideh, Carmel, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 5776931 19980707 <--  
AI US 1997-775533 19970109 (8)  
DT Utility  
FS Granted  
LN.CNT 1892  
INCL INCLM: 514/232.800  
INCLS: 514/322.000; 514/393.000; 514/394.000; 514/395.000; 544/139.000;  
546/199.000; 548/302.100  
NCL NCLM: 514/232.800  
NCLS: 514/322.000; 514/393.000; 514/394.000; 514/395.000; 544/139.000;  
546/199.000; 548/302.100  
IC [6]  
ICM: A61K031-535  
ICS: A61K031-445; A61K031-415; C09D413-00; C09D421-00; C09D235-02  
EXF 514/322; 514/232.8; 514/393; 514/394; 514/395; 548/302.1; 544/139;  
546/199  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 55 OF 66 USPATFULL on STN  
AN 1998:61669 USPATFULL  
TI Alpha IC adrenergic receptor antagonists  
IN Huff, Joel R., Gwynedd Valley, PA, United States  
Lee, Hee-Yoon, Yusung-Gu, Korea, Republic of  
Nerenberg, Jennie B., Maple Glen, PA, United States  
Thompson, Wayne J., Lansdale, PA, United States  
Bell, Ian M., Harleysville, PA, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5760054 19980602 <--  
AI WO 9528397 19951026 <--  
US 1996-722001 19961001 (8)  
WO 1995-US4590 19950413  
19961001 PCT 371 date  
19961001 PCT 102(e) date  
RLI Continuation-in-part of Ser. No. US 1994-229276, filed on 13 Apr 1994,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 4070  
INCL INCLM: 514/302.000  
INCLS: 514/321.000; 514/322.000; 514/324.000; 546/114.000; 546/198.000;  
546/199.000; 546/202.000  
NCL NCLM: 514/302.000

NCLS: 514/321.000; 514/322.000; 514/324.000; 546/114.000; 546/198.000;  
546/199.000; 546/202.000

IC [6]

ICM: A61K031-445

ICS: C07D401-04; C07D471-04; C07D471-10

EXF 514/322; 514/324; 514/321; 514/302; 546/114; 546/198; 546/199; 546/202;  
546/115

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 56 OF 66 USPATFULL on STN

AN 1998:48408 USPATFULL

TI Alpha 1b adrenergic receptor antagonists

IN Bock, Mark G., Hatfield, PA, United States

Patane, Michael A., Harleysville, PA, United States

Lumma, William C., Pennsburg, PA, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5747490 19980505

<--

AI US 1996-716041 19960919 (8)

PRAI US 1995-4501P 19950929 (60)

DT Utility

FS Granted

LN.CNT 1407

INCL INCLM: 514/233.800

INCLS: 514/255.000; 514/260.000; 544/116.000; 544/291.000

NCL NCLM: 514/233.800

NCLS: 514/252.170; 514/266.200; 514/266.220; 514/266.230; 544/116.000;  
544/291.000

IC [6]

ICM: A61K031-535

ICS: A01N043-60; C07D415-00; C07D239-72

EXF 544/116; 544/291; 514/233.8; 514/255; 514/260

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 57 OF 66 USPATFULL on STN

AN 1998:17310 USPATFULL

TI Morpholine and thiomorpholine tachykinin receptor antagonists

IN Dorn, Conrad P., Plainfield, NJ, United States

Finke, Paul E., Milltown, NJ, United States

Hale, Jeffrey J., Westfield, NJ, United States

MacCoss, Malcolm, Freehold, NJ, United States

Mills, Sander G., Woodbridge, NJ, United States

Shah, Shrenik K., Metuchen, NJ, United States

Chambers, Mark Stuart, North Bushey, England

Harrison, Timothy, Great Dunmow, England

Ladduwahetty, Tamara, Buckhurst Hill, England

Williams, Brian John, Great Dunnow, England

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5719147 19980217

<--

AI US 1995-525259 19950908 (8)

RI Continuation-in-part of Ser. No. US 1993-169889, filed on 17 Dec 1993,  
now abandoned which is a continuation-in-part of Ser. No. US 1993-61914,  
filed on 19 May 1993, now abandoned which is a continuation-in-part of  
Ser. No. US 1992-971448, filed on 4 Nov 1992, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992,  
now abandoned

DT Utility

FS Granted

LN.CNT 8352

INCL INCLM: 514/227.500

INCLS: 514/227.800; 514/228.200; 514/231.200; 514/231.500; 514/233.500;  
514/233.800; 514/235.200; 514/235.800; 514/236.200; 514/236.500;  
514/236.800; 514/237.200; 544/059.000; 544/060.000; 544/061.000;  
544/062.000; 544/058.100; 544/058.400; 544/111.000; 544/106.000;  
544/114.000; 544/122.000; 544/128.000; 544/129.000; 544/132.000;  
544/133.000; 544/137.000; 544/139.000; 544/140.000; 544/141.000;  
544/143.000; 544/145.000; 544/146.000; 544/148.000; 544/152.000;  
544/153.000

NCL NCLM: 514/227.500

NCLS: 514/227.800; 514/228.200; 514/231.200; 514/231.500; 514/233.500;  
514/233.800; 514/235.200; 514/235.800; 514/236.200; 514/236.500;  
514/236.800; 514/237.200; 544/058.100; 544/058.400; 544/059.000;  
544/060.000; 544/061.000; 544/062.000; 544/106.000; 544/111.000;  
544/114.000; 544/122.000; 544/128.000; 544/129.000; 544/132.000;  
544/133.000; 544/137.000; 544/139.000

IC [6]

ICM: A61K031-54

EXF ICS: A61K031-535; C07D413-04; C07D417-04; C07D279-12; C07D265-30  
514/236.2; 514/235.5; 514/235.8; 514/236.8; 514/237.2; 514/227.5;  
514/227.8; 514/228.2; 514/231.2; 514/231.5; 514/233.5; 514/233.8;  
514/236.5; 544/59; 544/60; 544/177; 544/158; 544/61; 544/62; 544/58.1;  
544/58.4; 544/106; 544/111; 544/114; 544/122; 544/128; 544/129; 544/132;  
544/133; 544/137; 544/139; 544/140; 544/141; 544/143; 544/145; 544/146;  
544/148; 544/152; 544/153

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 58 OF 66 USPATFULL on STN  
AN 1998:14789 USPATFULL  
TI Treatment of migraine with morpholine tachykinin receptor antagonists  
IN Dorn, Conrad P., Plainfield, NJ, United States  
Maccoss, Malcolm, Freehold, NJ, United States  
Hale, Jeffrey J., Westfield, NJ, United States  
Mills, Sander G., Woodbridge, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5716942 19980210 <--  
AI US 1995-450198 19950525 (8)  
RLI Division of Ser. No. US 1994-206771, filed on 4 Mar 1994, now abandoned  
DT Utility  
FS Granted  
LN.CNT 6755  
INCL INCLM: 514/090.000  
INCLS: 514/235.500; 514/236.200  
NCL NCLM: 514/090.000  
NCLS: 514/235.500; 514/236.200  
IC [6]  
ICM: A61K031-675  
ICS: A61K031-535  
EXF 514/90; 514/235.5; 514/236.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 59 OF 66 USPATFULL on STN  
AN 97:109895 USPATFULL  
TI Morpholine compounds are prodrugs useful as tachykinin receptor  
antagonists  
IN Dorn, Conrad P., Plainfield, NJ, United States  
Hale, Jeffrey J., Westfield, NJ, United States  
Maccoss, Malcolm, Freehold, NJ, United States  
Mills, Sander G., Woodbridge, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5691336 19971125 <--  
AI US 1995-525870 19950908 (8)  
RLI Continuation-in-part of Ser. No. US 1994-206771, filed on 4 Mar 1994,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 7292  
INCL INCLM: 514/236.200  
INCLS: 514/233.500; 514/235.200; 514/235.500; 514/235.800; 544/132.000;  
544/134.000; 544/139.000; 544/141.000; 544/143.000  
NCL NCLM: 514/236.200  
NCLS: 514/233.500; 514/235.200; 514/235.500; 514/235.800; 544/132.000;  
544/134.000; 544/139.000; 544/141.000; 544/143.000  
IC [6]  
ICM: C07D265-32  
ICS: C07D279-12; C07D413-04; C07D413-06; C07D413-14  
EXF 544/132; 544/134; 544/139; 544/141; 544/143; 514/235.2; 514/235.5;  
514/235.8; 514/233.5; 514/236.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 60 OF 66 USPATFULL on STN  
AN 97:107219 USPATFULL  
TI \*\*\*Calcium\*\*\* receptor-active molecules  
IN Brown, Edward M., Milton, MA, United States  
Fuller, Forrest H., Salt Lake City, UT, United States  
Hebert, Steven C., Wellesley, MA, United States  
PA Garrett, Jr., James E., Salt Lake City, UT, United States  
The Brigham & Women's Hospital, Inc., Boston, MA, United States (U.S.  
corporation)  
NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.  
corporation)  
PI US 5688938 19971118 <--  
AI US 1995-485588 19950607 (8)  
RLI Continuation-in-part of Ser. No. US 1994-353784, filed on 8 Dec 1994

which is a continuation-in-part of Ser. No. US 1993-9389, filed on 23 Feb 1993, now abandoned Ser. No. Ser. No. US 1993-141248, filed on 22 Oct 1993, now abandoned And Ser. No. US 1994-292827, filed on 19 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US -141248 which is a continuation-in-part of Ser. No. US -9389 which is a continuation-in-part of Ser. No. US 1993-17127, filed on 12 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-934161, filed on 21 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-834044, filed on 11 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-749451, filed on 23 Aug 1991, now abandoned

DT Utility

FS Granted

LN.CNT 6522

INCL INCLM: 536/023.500

INCLS: 435/069.100; 435/007.100; 435/290.100; 435/252.300; 435/320.100; 530/300.000; 530/350.000; 530/324.000; 530/326.000; 536/023.100; 536/024.310

NCL NCLM: 536/023.500

NCLS: 435/007.100; 435/069.100; 435/252.300; 435/320.100; 530/300.000; 530/324.000; 530/326.000; 530/350.000; 536/023.100; 536/024.310

IC [6]

ICM: C07K004-705

ICS: C12N015-12

EXF 435/7.1; 435/69.1; 435/240.1; 435/252.3; 435/320.1; 535/23.5; 535/23.1; 530/300; 530/350; 530/324; 530/326; 530/327; 530/329

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 61 OF 66 USPATFULL on STN

AN 97:83974 USPATFULL

TI Alpha1a adrenergic receptor antagonists

IN Payne, Linda S., Lansdale, PA, United States

Young, Steven D., Lansdale, PA, United States

Zaborowski, Mary Jo L., Westfield, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5668148 19970916 <--

AI US 1995-425969 19950420 (8)

DT Utility

FS Granted

LN.CNT 2240

INCL INCLM: 514/314.000

INCLS: 514/307.000; 514/318.000; 514/321.000; 514/322.000; 514/323.000; 514/324.000; 514/326.000; 514/367.000; 514/372.000; 514/373.000; 514/375.000; 514/378.000; 514/379.000; 514/394.000; 514/406.000; 546/139.000; 546/167.000; 546/193.000; 546/194.000; 546/196.000; 546/197.000; 546/198.000; 546/199.000; 546/201.000; 546/202.000; 546/205.000; 546/211.000; 548/152.000; 548/159.000; 548/206.000; 548/207.000; 548/217.000; 548/241.000; 548/247.000; 548/306.100; 548/361.100; 548/364.100; 548/364.400; 548/365.700

NCL NCLM: 514/314.000

NCLS: 514/307.000; 514/318.000; 514/321.000; 514/322.000; 514/323.000; 514/324.000; 514/326.000; 514/367.000; 514/372.000; 514/373.000; 514/375.000; 514/378.000; 514/379.000; 514/394.000; 514/406.000; 546/139.000; 546/167.000; 546/193.000; 546/194.000; 546/196.000; 546/197.000; 546/198.000; 546/199.000; 546/201.000; 546/202.000; 546/205.000; 546/211.000; 548/152.000; 548/159.000; 548/206.000; 548/207.000; 548/217.000; 548/241.000; 548/247.000; 548/306.100; 548/361.100; 548/364.100; 548/364.400; 548/365.700

IC [6]

ICM: A61K031-47

ICS: A61K031-415; A61K031-42; A61K031-425; A61K031-445; C07D401-04; C07D409-04

EXF 546/167; 546/194; 546/197; 546/211; 546/139; 546/193; 546/196; 546/198; 546/199; 546/201; 546/202; 546/205; 574/314; 574/318; 574/321; 574/326; 574/307; 574/322; 574/323; 574/324; 574/367; 574/372; 574/373; 574/375; 574/378; 574/379; 574/394; 574/406; 548/152; 548/159; 548/207; 548/217; 548/241; 548/306.1; 548/361; 548/364.1; 548/364.4; 548/365.7; 548/206; 548/247

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 62 OF 66 USPATFULL on STN

AN 97:76145 USPATFULL

TI Alpha-1a adrenergic receptor antagonists

IN Patane, Michael A., Harleysville, PA, United States

Bock, Mark G., Hatfield, PA, United States

Freidinger, Roger M., Lansdale, PA, United States

PA Ponticello, Rose Ann, Harleysville, PA, United States  
PI Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
AI US 5661163 19970826 <--  
AI US 1995-488272 19950607 (8)  
DT Utility  
FS Granted  
LN.CNT 1613  
INCL INCLM: 514/331.000  
INCLS: 514/330.000; 514/284.000; 546/215.000; 546/225.000  
NCL NCLM: 514/331.000  
NCLS: 514/284.000; 514/330.000; 546/215.000; 546/225.000  
IC [6]  
ICM: A61K031-445  
ICS: C07D211-36  
EXF 514/316; 514/318; 514/326; 514/327; 514/331; 514/330; 514/284; 546/194;  
546/205; 546/206; 546/213; 546/214; 546/215; 546/221; 546/225  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 63 OF 66 USPATFULL on STN  
AN 97:49744 USPATFULL  
TI Process for preparing morpholine tachykinin receptor antagonists  
IN Dorn, Conrad P., Plainfield, NJ, United States  
Hale, Jeffrey J., Westfield, NJ, United States  
Finke, Paul E., Milltown, NJ, United States  
MacCoss, Malcolm, Freehold, NJ, United States  
Mills, Sander G., Woodbridge, NJ, United States  
Shah, Shrenik K., Metuchen, NJ, United States  
Chambers, Mark S., Watford Harts, England  
Harrison, Timothy, Great Dunmow, England  
Ladduwahetty, Tamara, Buckhurst Hill, England  
Williams, Brian J., Great Dunnow, England  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5637699 19970610 <--  
AI US 1995-445489 19950522 (8)  
RLI Division of Ser. No. US 1993-169889, filed on 17 Dec 1993, now abandoned  
which is a continuation-in-part of Ser. No. US 1993-61914, filed on 19  
May 1993, now abandoned which is a continuation-in-part of Ser. No. US  
1992-971448, filed on 4 Nov 1992, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 6269  
INCL INCLM: 540/524.000  
INCLS: 544/111.000; 544/114.000; 544/121.000; 544/122.000; 544/124.000;  
544/129.000; 544/132.000; 544/133.000; 544/134.000; 544/137.000;  
544/139.000; 544/140.000; 544/141.000; 544/143.000; 544/148.000;  
544/153.000; 544/174.000  
NCL NCLM: 540/524.000  
NCLS: 544/111.000; 544/114.000; 544/121.000; 544/122.000; 544/124.000;  
544/129.000; 544/132.000; 544/133.000; 544/134.000; 544/137.000;  
544/139.000; 544/140.000; 544/141.000; 544/143.000; 544/148.000;  
544/153.000; 544/174.000  
IC [6]  
ICM: C07D413-02  
ICS: C07D265-28; C07D265-30; C07D265-34  
EXF 544/174; 544/139; 544/153; 544/146; 544/137; 544/143; 544/133; 544/138;  
544/114; 544/140; 544/124; 544/122; 544/141; 544/127; 544/132; 544/134;  
544/111; 544/148; 544/121; 544/129; 540/524  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 64 OF 66 USPATFULL on STN  
AN 97:31715 USPATFULL  
TI Alpha-1a adrenergic receptor antagonists  
IN Patane, Michael A., Harleysville, PA, United States  
Bock, Mark G., Hatfield, PA, United States  
Friedinger, Roger M., Lansdale, PA, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5620993 19970415 <--  
AI US 1995-488267 19950607 (8)  
DT Utility  
FS Granted  
LN.CNT 1220  
INCL INCLM: 514/321.000  
INCLS: 514/284.000; 514/252.000; 514/253.000; 514/318.000; 514/326.000;  
514/327.000; 514/328.000; 514/330.000; 514/331.000; 544/224.000;

NCL NCLM: 544/238.000; 544/239.000; 544/240.000; 546/198.000; 546/194.000;  
546/193.000; 546/213.000; 546/214.000; 546/215.000; 546/077.000;  
546/217.000; 546/219.000; 546/221.000; 546/228.000; 546/234.000  
NCLS: 514/321.000  
514/252.010; 514/252.030; 514/252.050; 514/252.060; 514/284.000;  
514/318.000; 514/326.000; 514/327.000; 514/328.000; 514/330.000;  
514/331.000; 544/224.000; 544/238.000; 544/239.000; 544/240.000;  
546/077.000; 546/193.000; 546/194.000; 546/198.000; 546/213.000;  
546/214.000; 546/215.000; 546/217.000; 546/219.000; 546/221.000;  
546/228.000; 546/234.000

IC [6]  
ICM: A61K031-445  
ICS: C07D211-42

EXF 546/198; 546/194; 546/77; 546/215; 546/217; 546/219; 546/221; 546/228;  
546/234; 546/193; 546/213; 546/214; 514/252; 514/253; 514/284; 514/318;  
514/321; 514/326; 514/327; 514/328; 514/330; 514/331; 544/238; 544/224;  
544/239; 544/240

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 65 OF 66 USPATFULL on STN  
AN 96:38897 USPATFULL  
TI Naphthyl bradykinin receptor antagonists  
IN Bruns, Jr., Robert F., Carmel, IN, United States  
Gehlert, Donald R., Indianapolis, IN, United States  
Howbert, J. Jeffry, Bellevue, WA, United States  
Lunn, William H. W., Indianapolis, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 5514675 19960507  
AI US 1994-327519 19941020 (8) <--  
DT Utility  
FS Granted

LN.CNT 1129  
INCL INCLM: 514/229.500  
INCLS: 514/248.000; 514/280.000; 514/284.000; 514/393.000; 514/400.000;  
514/724.000; 568/303.000; 568/305.000; 568/308.000; 568/326.000  
NCL NCLM: 514/229.500  
NCLS: 514/248.000; 514/280.000; 514/284.000; 514/393.000; 514/400.000;  
514/724.000; 568/303.000; 568/305.000; 568/308.000; 568/326.000

IC [6]  
ICM: C07C049-203  
ICS: C07C049-115; C07C049-00  
EXF 514/229.5; 514/248; 514/280; 514/284; 514/393; 514/400; 514/724; ;  
568/303; 568/305; 568/308; 568/326  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 66 OF 66 USPATFULL on STN  
AN 96:36566 USPATFULL  
TI Treatment of emesis with morpholine tachykinin receptor antagonists  
IN Dorn, Conrad P., Plainfield, NJ, United States  
MacCoss, Malcolm, Freehold, NJ, United States  
Hale, Jeffrey J., Westfield, NJ, United States  
Mills, Sander G., Woodbridge, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5512570 19960430 <--  
AI US 1995-450507 19950525 (8)  
RLI Division of Ser. No. US 1994-206771, filed on 4 Mar 1994  
DT Utility  
FS Granted  
LN.CNT 6501

INCL INCLM: 514/236.200  
INCLS: 514/235.500; 514/235.800; 514/236.500; 514/236.800; 514/237.200  
NCL NCLM: 514/236.200  
NCLS: 514/235.500; 514/235.800; 514/236.500; 514/236.800; 514/237.200

IC [6]  
ICM: A61K031-535  
ICS: C07D413-00  
EXF 514/235.8; 514/236.5; 514/236.2; 514/236.8; 514/235.5; 514/237.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

STN INTERNATIONAL LOGOFF AT 12:29:03 ON 26 AUG 2004